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ABSTRACT
Tyrosine-phosphorylated FAK is required for the hypertrophic response of
cardiomyocytes to growth factors and mechanical load, but the role of FAK serine
phosphorylation in this process is unknown. Endothelin-1 (ET-1; 1-100nM, 230min) and other hypertrophic factors induced a time- and dose-dependent
increase in FAK-S910 phosphorylation in neonatal rat ventricular myocytes
(NRVM). FAK-S910 phosphorylation required ETAR-dependent activation of
PKCδ and Src via parallel Raf-1→MEK1/2→ERK1/2 and MEK5→ERK5 signaling
pathways. Using co-immunoprecipitation, TIRF-microscopy and FRAP, ET-1
stimulation of NRVM expressing a nonphosphorylatable, S910A-FAK mutant
decreased the interaction of paxillin and vinculin within costameres. This
interaction was important in stabilizing α-actinin within the protein complex, as
evident by a decrease in kFRAP for α-actinin-YFP. The S910A-FAK mutant also
blocked ET-1 induced NRVM spreading and cyotoskeletal reorganization. Finally,
we found that FAK was serine-phosphorylated at multiple sites in nonfailing,
human LV tissue. FAK-S910 phosphorylation and ERK5 expression were
dramatically reduced in patients undergoing heart transplantation for end-stage
DCM. FAK undergoes S910 phosphorylation via PKCδ and Src-dependent
pathways that are important for cell spreading and sarcomere reorganization.
Reduced

FAK-S910

phosphorylation

may
xvi

contribute

to

sarcomere

disorganization in DCM

xvii

CHAPTER ONE
INTRODUCTION
1. Cardiac hypertrophy
Cardiovascular disease (CVD) remains the most common cause of
mortality in the Western world (Heidenreich et al., 2011). An estimated
81,100,000 American adults (more than 1 in 3) have one or more types of CVD.
Of these, 38,100,000 are estimated to be 60 years of age or older. The estimated
direct and indirect cost of CVD for 2010 is $503.2 billion. One feature common to
most forms of cardiovascular disease is cardiac hypertrophy. Enlargement of
individual cardiac muscle cells, or cardiomyocyte hypertrophy, accompanies
virtually all forms of cardiac hypertrophy. In the Framingham Heart Study,
investigators have shown that increased left ventricular mass, or left ventricular
hypertrophy (LVH), is an independent risk factor for the development of
congestive heart failure, arrhythmia and sudden death (Konstam et al., 2011;
Levy et al., 1990; Levy et al., 2002);
Cardiomyocyte hypertrophy can be separated into physiological and
pathological hypertrophy. Physiological hypertrophy is usually caused by
exercise or pregnancy, and is characterized by normal cardiac morphology (i.e.
no fibrosis or apoptosis) and normal or enhanced cardiac function. Physiological
hypertrophy is a reversible process, in that cell enlargement disappears promptly
1
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after the termination of pregnancy, or cessation of exercise training. In contrast,
pathological hypertrophy is associated with increased fibrosis, apoptosis and
decreased cardiac function, and is caused by hypertension, atherosclerotic
coronary artery disease, valvular heart disease, or mutation in several genes
encoding contractile proteins.(Bernardo et al., 2010; Konstam et al., 2011;
McMullen and Jennings, 2007)

2. Subclassification of pathological hypertrophy.
Pathological cardiac hypertrophy can involve any or all chambers of the
heart. Most commonly, the LV is affected, although the pattern of growth can
differ depending on the underlying cardiac disease. LVH can be sub-classified as
either "pressure-overload" or "volume-overload" hypertrophy, depending upon
the form of the mechanical overload affecting LV systolic or diastolic work. For
instance, LV pressure overload is caused by an increase in LV systolic pressure,
due to either systemic arterial hypertension, or aortic stenosis. LV volume
overload hypertrophy is often caused by an increase in LV diastolic volume, as
occurs in mitral regurgitation. The pattern of ventricular growth differs between
these differing hemodynamic stimuli. LV cardiomyocytes respond to pressure
overload by undergoing concentric hypertrophy (increased thickness of
ventricular walls with little or no change in chamber volume), whereas volume
overload produces eccentric hypertrophy (increased chamber volume with
ventricular wall thickness increased in proportion with chamber dimensions),
respectively. In both types of hypertrophy, the size of the cardiomyocytes
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increases, with the resulting cellular enlargement paralleled by an increase in the
number of existing sarcomeres. The addition of these sarcomeres occurs either
in parallel (concentric LVH) or in series (eccentric LVH). Nevertheless, both types
of hemodynamic stimuli require a cellular mechanism that leads to the assembly
of new sarcomeres.(Frey and Olson, 2003; Lorell and Carabello, 2000)

3. Hemodynamic vs. neurohormonal induction of cardiac
hypertrophy.
Although hemodynamic overload is the major stimulus for the induction of
cardiac hypertrophy, it is clear that neurohormonal factors also play an important
role. For instance, Baker and co-workers have shown that that low doses of
angiotensin II (AngII) administered to rats produced LVH without a significant
increase in blood pressure (Morgan and Baker, 1991). Similarly, patients with
growth hormone secreting pituitary tumors (i.e., acromegaly) develop LVH
without necessarily developing concomitant hypertension, but invariably develop
LVH with diastolic dysfunction (Stewart et al., 1992). There appears to be a close
interplay between neurohormonal factors that induce LVH, and also produce
hypertension. However, numerous studies performed in isolated cardiomyocytes
in the absence of hemodynamic stimuli have revealed that neurohormones can
produce cardiomyocyte hypertrophy even in the absence of mechanical overload.
Indeed, signaling pathways activated by neurohormonal and mechanical stimuli
share many components.(Rohini et al., 2010)

4
4. Hypertrophic signal transduction mechanisms.
As indicated above, the stimuli for cardiomyocyte hypertrophy can be
broadly segregated into biomechanical or stretch-sensitive mechanisms, and
neurohumoral mechanisms that are associated with the release of hormones,
cytokines, chemokines and peptide growth factors. These various stimuli are
thought to converge on a number of intracellular signal transduction circuits to
mediate the cardiomyocyte growth response.
Neurohumoral

mechanisms:

Several

neurohumoral

and

autocrine/paracrine factors such as catecholamines (e.g., norepinephrine and
epinephrine)(Gans and Cater, 1970), endothelin-1 (ET-1)(Ito et al., 1991; Suzuki
et al., 1991), AngII and Insulin-like Growth factor-1 (IGF-1)(Ito et al., 1993) are
involved in mediating cardiomyocyte growth. These ligands are sensed by
cardiomyocytes through several different membrane-bound cell surface receptors
such as G-protein-coupled receptors (GPCRs) and receptor tyrosine kinases
(RTKs).
Mechanical mechanisms: In addition to signalling events that are initiated
by ligand–receptor interactions, cardiomyocytes can directly detect mechanical
deformation or stretch through an internal sensory apparatus. One such
apparatus involves integrins, which are heterodimeric transmembrane receptors
(consisting of α- and β-subunits) that link the extracellular matrix (ECM) to the
intracellular cytoskeleton.(Kira et al., 1994; Sadoshima et al., 1992; Sadoshima
et al., 1993)
Both mechanisms transduce extracellular signals into the cell and activate
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downstream signalling pathways. From experiments using isolated neonatal and
adult cardiomyocytes in long-term culture, and animal models of human disease,
studies have shown that a variety of signalling proteins are important mediators
of cardiomyocyte hypertrophy. These include the mitogen-activated protein
kinases (MAPKs), the calcium-activated phosphatase calcineurin, nuclear factor
of activated T-cells (NFAT), and the phosphatidylinositol 3-kinase (PI3K)–
AKT/protein kinase B (PKB)–mammalian target of rapamycin (mTOR) signaling
pathways. (Frey and Olson, 2003; Heineke and Molkentin, 2006; Rohini et al.,
2010)
For example, there is a wealth of information regarding the role of the
peptide growth factor ET-1 in the induction of cardiac hypertrophy and its
transition to heart failure. Cardiomyocytes express both Endothelin A (ETAR) and
Endothelin B (ETBR) transmembrane receptor isoforms. The predominant
isoform in rat cardiac myocytes is the ETAR. The ETAR is a Gq-coupled
receptor.(Sugden, 2003a; Sugden and Clerk, 2005) When ET-1 binds to the
ETAR, it stimulates the hydrolysis of membrane phosphatidylinositol 4,5bisphosphate (Ptd(4,5)-InsP2) to diacylglycerols (DAGs) and inositol 1,4,5trisphosphate (IP3). DAG remains in the sarcolemmal membrane, but IP3 is
soluble and diffuses into the cytoplasm and activates receptors located within the
endoplasmic reticulum, an intracellular membrane system and storage site for
Ca2+. IP3 regulates intracellular Ca2+ movements in many cells types, including
cardiomyocytes (Bare et al., 2005; Moschella and Marks, 1993; Perez et al.,
1997). Along with the released Ca2+, DAG is an important activator of protein

6
kinase C (PKC). Several isoenzymes of PKC are activated by binding to DAGs.
When DAGs bind to PKC, the kinase translocates from the cytoplasm to various
membranes and this causes PKC activation. Once activated, PKC isoenzymes
can phosphorylate and activate several downstream signaling pathways, such as
the

Ras-Raf-MEK1/2-ERK1/2,

PKD-HDAC,

and

GSK3β-NFAT

pathways.

(Malhotra et al., 2001; Sugden, 2003a)

5. Stretch-induced hypertrophic signal transduction.
In cardiomyocytes, mechanical stimulation can also induce hypertrophic
responses through the activation of downstream intracellular signaling pathways.
Mechanical loading increases the rate of protein synthesis, and re-programs
gene expression leading to the re-induction of a set of genes normally expressed
during fetal life. The processing of most mechanosensory signals is likely to
involve the ECM-integrin-costameric protein complex, mechanosensors within
the sarcolemmal membrane and Z discs, stretch-activated ion channels and
calcium effectors (Chu et al., in press). Furthermore, mechanical stimulation can
also induce the cellular release of AngII, ET-1, and other peptide growth factors,
causing transactivation of their cognate receptors (both GPCRs and RTKs).(Kaye
et al., 1996; Naka et al., 2008; Sadoshima et al., 1993; Yamazaki et al., 1996)
Mechanosensory signals then can trigger several downstream effectors such as
the MAPK signaling cascades (i.e., ERKs, JNKs, and p38MAPK); pathways that
involve PI3K, AKT, and mTOR; the JAK-STAT signaling pathway; and Ca2+dependent pathways involved in the activation of Calcineruin A (CnA) and Ca2+-
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calmodulin-dependent protein kinases. Thus mechanosensory pathways share
critical

components

norepinephrine,

with

ET-1,

signaling

AngII,

and

pathways
other

activated

peptide

in

growth

response
factors

to
and

cytokines.(Molkentin and Dorn, 2001; Sadoshima and Izumo, 1997a; Sadoshima
and Izumo, 1997b; Sugden, 2003b; Welch et al., 2002)

6

Cardiomyocyte

remodeling:

sarcomerogenesis

and

myofibrillogenesis.
The induction of cardiomyocyte hypertrophy is one component of a larger
adaptive response that is termed cardiac remodeling. The remodeling process
affects all of the cellular components of the heart, including the cardiomyocytes,
cardiac fibroblasts, and the cellular components of the vasculature. In addition,
there are profound alterations in the cardiac ECM.

With respect to the

cardiomyocytes, these cells adapt to increased hemodynamic load and the
autocrine/paracrine release of growth factors, by undergoing a process that
Gerdes has termed cardiomyocyte structural remodeling(Gerdes et al., 1988).
Depending upon

the

nature of

the hemodynamic overload,

individual

cardiomyocyte change shape, and undergo either length or width remodeling, or
both(Gerdes, 2002; Gerdes et al., 1988; Gerdes and Capasso, 1995; Gerdes et
al., 1995; Gerdes and Kasten, 1980; Gerdes et al., 1992). These alterations in
cell shape are further characterized by the addition of new sarcomeres either in
series or in parallel. Biomechanical and neurohumoral mechanisms can then
induce the addition of sarcomeres to existing myofilaments (so called
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“sarcomerogenesis”). These stimuli can also cause the formation of new
sarcomeres where few if any are present (so called “myofibrillogenesis”). Both
myofibrillogenesis and sarcomerogenesis ultimately result in the assembly of
newly synthesized contractile proteins into functional sarcomeres.
During development, an important site for new myofibril formation is the
costamere, which provides a physical coupling of the cardiomyocyte to its ECM,
thereby linking the sarcolemmal membrane to peripheral Z-discs. Costameres
were first described as vinculin-containing, rib-like bands that encircle the
cardiomyocyte perpendicular to its long axis.(Bloch and Gonzalez-Serratos, 2003;
Danowski et al., 1992; Ervasti, 2003; Pardo et al., 1983a; Pardo et al., 1983b).
Costameres comprise cytoskeletal proteins, such as talin, vinculin and α-actinin;
and signalling molecules, such as focal adhesion kinase (FAK), integrin-linked
kinase (ILK) and the receptor for activated C kinase (RACK1). In cultured
cardiomyocytes, costameres reorganize to form adhesion structures that are
similar to typical focal adhesions found in nonmuscle cells. Modification of the
ECM can induce a dynamic reconfiguration of myocyte shape and intracellular
architecture, which includes the reorganization of existing sarcomeres.(Bray et
al., 2008)
Myofibrillogenesis is a highly organized and complex process that
coordinates the assembly of focal adhesion components, cytoskeletal proteins,
and contractile elements into a complex, 3-dimensional array. Costamere
provides docking site for the addition of new sarcomere both in series or parallel.
Initial studies examined fixed muscle preparations using light microscopy, and
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observed nonstriated fibers close to the cell membrane of developing skeletal
muscle (Gard and Lazarides, 1980). Sanger and co-workers extended these
observations by microinjection of cDNAs encoding fusion proteins of GFP to
study the process of myofibrillogenesis in living cells.(Sanger et al., 1986) These
landmark studies have shown that the structural precursor of mature sarcomeres,
so called “premyofibrils” assemble at the leading edge of the spreading muscle
cell.

Premyofibrils are composed of mini-sarcomeres (α-actinin containing Z-

bodies) with muscle actin, actin-binding proteins, and the nonmuscle isoform of
myosin, myosin IIB. They proposed that three different types of myofibrils are
formed sequentially during myofibrillogenesis. First, premyofibrils consist of thin
filaments with periodic mini-A-Bands. Second, nascent myofibrils include
nonmuscle isoform of myosin IIB and unbanded muscle-specific myosin II. Third,
mature myofibrils only enclose muscle-specific myosin II in the A-band. (Sanger
et al., 2010) Disrupting the formation of non-muscle myosin II filaments by
inhibiting myosin light chain kinase caused the loss of premyofibrils and
disorganization of myosin thick filaments.(Du et al., 2003; Du et al., 2008)
Premyofibril formation is stimulated by both neurohumoral (AngII) and
mechanical hypertrophic stimuli.(Aoki et al., 1998; Sharp et al., 1997) Besides
nonmuscle myosin IIB, several proteins also play an important role in
myofibrillogenesis, such as Neubulin(McElhinny et al., 2005; Nwe and Shimada,
2000; Takano et al., 2010), N-WASP(Takano et al., 2010), titin (Ayoob et al.,
2000; Gregorio et al., 1998; Peckham et al., 1997), obscurin(KontrogianniKonstantopoulos

et

al.,

2004)

(Kontrogianni-Konstantopoulos

A

et

al
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2004)(Borisov et al., 2008) and N-RAP.(Carroll et al., 2004; Lu et al., 2005)
Most studies of sarcomerogenesis and myofibrillogenesis are based on
developmentally immature cells in culture. Length-remodeling processes in adult
skeletal muscle have shown somewhat different results, in that new sarcomere
formation begins close to myotendon junctions(Dix and Eisenberg, 1990). In
cardiac hypertrophy studies, Perriard and co-workers have shown that
intercalated discs are not well organized and have a denser architecture in
myopathic hearts(Perriard et al., 2003). Other studies also demonstrate that new
sarcomeres can be incorporated into the middle of the fiber or by enhancement
at the intercalated discs, as shown in human skeletal muscle and rat
cardiomyocytes(Yu and Russell, 2005; Yu and Thornell, 2002) (Yu et al., 2003).
It is possible that the costamere and the Z-disc within existing myofibrils are both
key factors for the addition of new filaments in mature muscle cells.
For this reason, models of de novo sarcomere formation that rely on
premyofibril formation initiated at the cell membrane might not be identical to the
adult cell remodeling process in the intact heart subjected to hypertrophic stimuli
in vivo. However, studies of sarcomere formation during development, or in cell
culture systems still have been very useful in defining specific cytoskeletal
proteins and signaling pathways that may be important in regulating growth, and
identifying their molecular mechanisms.

7. Focal adhesion kinase
As mentioned above, FAK is an important signaling kinase that may be
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involved in the earliest steps of myofibrillogenesis. FAK belongs to the nonreceptor PTK family and is expressed in most tissues and cell types. FAK was
first identified in 1992 by several different groups as a substrate of the viral
oncogene v-Src. (Guan and Shalloway, 1992; Hanks et al., 1992; Kornberg et al.,
1992; Schaller et al., 1992) The focal adhesion PTK family consists of FAK and
related adhesion focal tyrosine kinase (RAFTK)/proline-rich tyrosine kinase 2
(Pyk2)(also known as CAK-ß or CADTK).(Avraham et al., 2000) FAK and Pyk2
protein sequences show approximately 48% identity (65% similarity) and have a
similar domain structure: a unique N-terminus containing a protein 4.1, ezrin,
radixin and moesin homology domain (FERM domain); a centrally located protein
tyrosine kinase catalytic domain, three proline-rich regions, and a focal adhesion
targeting (FAT) domain at the C-terminus (Figure 1). FAK homologues exhibit an
overall sequence identity of 90% in different species, such as human (Whitney et
al., 1993), mouse (Hanks and Polte, 1997), chicken(Schaller et al., 1992), and
frog. FAK has 6 tyrosine phosphorylation sites that undergo phosphorylation in
vivo: two sites (Y397 and Y407) within the FAK N-terminal domain; two sites
(Y576 and Y577) within the kinase domain activation loop; and two sites (Y861
and Y925) within the C-terminal domain (Figure 1). Four FAK tyrosine
phosphorylation sites (Y397, 576, 577, and 925) are conserved at analogous
positions in Pyk2 (Y402, 579, 580 and 881) (Figure 1). FAK also contains several
different serine phosphorylation sites, but there is currently no evidence to
demonstrate that Pyk2 also contains functional serine phosphorylation sites. In
early studies, investigators have shown that tyrosine phosphorylation of FAK is a
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rapid event that is associated with focal adhesion formation and the activation of
several downstream signaling pathways. (Cabodi et al., 2010; ChrzanowskaWodnicka and Burridge, 1994; Gates et al., 1994; Lipfert et al., 1992; Schaller,
2010; Shattil et al., 1994)
The FAK N-terminal FERM domain generally consists of three globular
subdomains or lobes (F1, F2, and F3) arranged in a “clover leaf”
structure.(Ceccarelli et al., 2006) This domain can directly interact with bindingprotein partners and/or phosphoinositides. It also contains one proline-rich region
of unknown significance. The FAK FERM domain is believed to function as an
autoinhibitory domain, thereby regulating its own kinase activity, downstream
signaling, and biological responses. It also contains a nuclear export signal (NES)
and a nuclear localization signal (NLS) (Figure 1)(Lim et al., 2008; Ossovskaya et
al., 2008). From the crystal structure of a fragment of FAK containing both the
FERM and kinase domains in the auto-inhibited state, Ceccarelli et al. showed
that the FERM domain binds directly to the kinase C-lobe when FAK is autoinhibited.(Ceccarelli et al., 2006; Lietha et al., 2007) This interaction can impede
access to the active site and protect FAK from phosphorylation by Src. The
inhibitory interaction between the FERM domain and the kinase domain involves
the F2 lobe of the FERM domain and a site on the C-lobe of the kinase domain.
The Y397 auto-phosphorylation site on FAK, which is located in a linker segment
connecting the FERM and kinase domains, is also sequestered from the active
site by an interaction with the FERM F1 subdomain (Lietha Daniel et al 2007)
(Figure 2). When Y397 is phosphorylated, an adjacent Pro motif forms a Src
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homology 2 (SH2) domain and Src homology 3 (SH3) domain, which recruit Src
to FAK(Frame et al., 2010).
The FERM domain also interacts with different binding partners, resulting
in different interactions that (a) recruit FAK into specific protein complexes; and
(b) induce an active FAK conformation. Previous studies have shown that the
FAK FERM domain can bind to RACK1) (Serrels et al., 2010), actin-related
protein 3 (Serrels et al., 2007), p53 (Lim et al., 2008), MDM2(Lim et al., 2008),
epidermal growth factor receptor (Sieg et al., 2000), c-Met (Chen and Chen,
2006), ezrin (Poullet et al., 2001), epithelial and endothelial tyrosine kinase
(Chen et al., 2001), phosphatidylinositol-4,5-bisphosphate (Ptdins(4,5)P2) (Cai et
al., 2008) and β-integrins (Cooper et al., 2003; Schaller et al., 1995).
The FAK kinase domain shares sequence similarity with other RTKs and
non-RTKs. Studies have shown that the transient dimerization of FAK leads to
intermolecular phosphorylation of FAK at the Y397 residue (Toutant et al., 2002).
Phosphorylation at Y397 site creates a high-affinity binding site for proteins with
SH2 domains, including Src family kinases (SFKs)(Cobb et al., 1994; Schaller et
al., 1994; Xing et al., 1994) and subsequently leads to Src-dependent
transphosphorylation of FAK at Y576 and Y577 within the kinase domain.
Phosphorylations at Y397, Y576 and Y577 sites are important for enhancing FAK
catalytic activity and downstream signaling. Besides forming the docking site for
Src, phosphorylated Y397 can also interact with several other proteins, including
p120RasGAP, the p85 subunit of PI3K, growth-factor-receptor bound protein
7(GRB7), phospholipase Cγ (PLCγ), suppressor of cytokine signaling-3 (SOCS-3)
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and the Shc adaptor protein(Akagi et al., 2002; Carloni et al., 1997; Chen et al.,
1996; Chen and Guan, 1994; Han and Guan, 1999; Liu et al., 2003; Takahashi et
al., 1999). The kinase domain can also interact with FAK interacting protein of
200kDa (FIP200) and this interaction can regulate the FAK catalytic activity.(Abbi
et al., 2002)
The C-terminal domain of FAK contains two proline-rich regions and the
FAT domain. The two proline-rich regions can serve as binding sites for SH3
domain-containing proteins. The first proline-rich region can interact with
p130CAS(Harte et al., 1996; Polte and Hanks, 1995) and the second proline-rich
region can interact with a GTPase activating protein (GAP) for Rho (GRAF) and
a GAP for Arf 1 and Arf 6 (Liu et al., 2002b; Randazzo et al., 2000; Taylor et al.,
1998; Taylor et al., 1999) A tyrosine phosphorylation site (Y861) is located
adjacent to the second proline-rich region. This site is regulated by the FAK-Src
signaling complex.(Calalb et al., 1996). The C-terminal domain also contains the
FAT domain, which is important for regulating the localization of FAK.(Hildebrand
et al., 1993) The FAT domain can directly interact with talin and paxillin, which
helps FAK interact with integrins.(Chen et al., 1995; Hildebrand et al., 1995)
Within the FAT domain, there exists another tyrosine phosphorylation site at
Y925. The Y925 residue is located at the beginning of the first α-helix of the FAT
domain, and is also regulated by the FAK-Src signaling complex. When FAKY925 is phosphorylated, it can form an SH2 binding site for the adaptor protein
Growth factor receptor-bound protein 2 (GRB2) (Schlaepfer et al., 1994). The
localization of FAK is important for cell adhesion-dependent activation of FAK
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signaling (Duncan et al., 1996; Lipfert et al., 1992). Mutation of the FAK FAT
domain leads to its inability to localize to focal adhesions, thereby attenuating
FAK’s tyrosine phosphorylation at multiple sites in response to cell adhesion to
fibronectin.(Shen and Schaller, 1999; Tahiliani et al., 1997) Futhermore,
dissolution of the actin cytoskeleton (with agents like cytochalasin D or latrunculin
A) also prevents FAK activation.(Duncan et al., 1996; Lipfert et al., 1992; Mehta
et al., 2002)

8. FAK serine phosphorylation
FAK function is not only regulated by tyrosine phosphorylation, but also
can be affected by the phosphorylation of specific serine residues. The first study
to address the role of FAK serine phosphorylation found that integrin binding to
the ECM induced S148 and S151 phosphorylations on the autonomously
expressed C-terminal domain of FAK, known as FAK-related non-kinase (FRNK).
These residues are equivalent to FAK S842 and S845 in mouse FAK. Serine
phosphorylation of FRNK required protein kinase A (PKA), but the function of
S148 and S151 phosphorylation on FRNK remains unclear. (Richardson et al.,
1997) From a detailed mass spectrometry (MS) study, Parsons’s group then
showed that chicken FAK also contains 15 serine and 5 threonine residues,
whereas human FAK contains 15 serine and 4 threonine residues, and mouse
FAK contains 14 serine and 4 threonine residues that can be phosphorylated in
vitro. They noted the juxtaposition of phosphoserine-, phosphothreonine- and
phosphotyrosine-containing residues, and suggested that there is coordination of
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these phosphorylation sites on FAK by different serine/theronine (S/T) and
tyrosine kinases. Within these 15 serine residues, several residues have been
studied which can be regulated by different kinases.(Grigera et al., 2005)
In the N-terminal domain of FAK, two possible S/T phosphorylation sites
(T13 and S29) were identified, and both sites are conserved between human,
mouse and frog FAK. Around the autophosphorylation site (Y397), several
possible S/T phosphorylation sites (S390, S392 and T406) have also been
identified by mass spectrometry.(Grigera et al., 2005) However, the regulation
and functional significance of these S/T phosphorylation sites are still not clear.
The kinase domain of FAK contains three serine phosphorylation sites (S517,
S601 and S695) and one threonine site (T600). Wang et al. have demonstrated
that

extracelluar

pressure

can

promote

FAK

S517,

S601

and

S695

phosphorylations, but inhibits FAK T600 phosphorylation. Pressure-induced FAK
S517, S601 and S695 phosphorylations occurred through an AKT1-dependent
pathway, which in turn enhanced FAK-Y397 phosphorylation and adhesion in
response to an increase in extracellular pressure. (Wang and Basson, 2011)
The C-terminal domain of FAK also contains several S/T phosphorylation
sites (T700, S708, S722, S725/S726, S732, S766, S843, S894 and S910), and
the regulation and functional significance of several serine phosphorylation sites
have been studied.(Grigera et al., 2005) FAK S722 and S732 phsophorylation
sites are located directly adjacent to the first proline-rich region, which is a
p130Cas binding site.(Harte et al., 1996; Polte and Hanks, 1995) S722
phosphorylation is regulated by glycogen synthase 3 β (GSK3β) during cell
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spreading, and is dephosphorylated by the protein phosphatase 1(PP1). The
S722 phosphorylation site also has an inhibitory effect on FAK activity and is
important in regulating cell spreading and migration. (Bianchi et al., 2005) Ma et
al. demonstrated that phosphorylation of S722 can modulate the FAK and
p130Cas interaction.(Ma et al., 2001) S732 phosphorylation is regulated by Rhodependent kinase (ROCK) during VEGF stimulation. In the spontaneously
hypertensive-heart failure (SHHF) rat model, FAK S722 phosphorylation is
significantly increased in LV myocytes, and this paper was the first evidence to
show that FAK can be serine phosphorylated in cardiomyocytes.(Yi et al., 2003;
Zhong et al., 2008), FAK S732 is regulated by ROCK, and is essential for the
Pyk2-dependent phosphorylation of FAK at Y407. These two steps are important
for VEGF-induced endothelial cell migration.(Le Boeuf et al., 2006) FAK S732 is
also phosphorylated by cyclin-dependent kinase 5 (CDK5) and is critical for the
organization of a small network of microtubules that partially encompasses the
nucleus. A FAK S732A mutation disrupted the microtubule network and impaired
both nuclear movement in vitro, and neuronal migration in vivo. (Xie et al., 2003)
Another study showed that FAK S732 phosphorylation is involved in the
interaction between FAK and dynein, and this interaction plays a role in the
regulation for centrosomal function. (Park et al., 2009) In FAK-null primary
endothelial cells, overexpression of a FAK S732A mutant could rescue cell
migration but not proliferation or tubulogenesis.(Park et al., 2009) These data
suggest that FAK S722 phosphorylation is regulated by GSK3β and plays a role
in FAK and p130Cas interaction. FAK S732 phosphorylation is regulated by

18
CDK5 or ROCK and its phosphorylation is important in centrosome function and
microtube organization during mitosis.
The FAK S843 phosphorylation site is located between the first and
second proline-rich regions. Fan et al. have demonstrated that stimulation of
Swiss 3T3 cells with bombesin, vasopressin, or bradykinin induced FAK S843
phosphorylation. Cells treated with different agents that inhibited agonist-induced
intracellular

Ca2+

signaling

also

attenuated

agonist-induced

FAK-S843

phosphorylation. Interestingly, a FAK S843A mutation enhanced phosphorylation
at Y397, suggesting that FAK S843 phosphorylation modulates the Y397
phosphorylation site. This modulation is important in FAK-mediated cell shape
and migration.(Fan et al., 2005; Jacamo et al., 2007)
The FAK-S910 phosphorylation site is located close to the first helix of the
FAT domain, and has been studied in different cell types. Hunger-Glaser et al
have shown that stimulation of Swiss 3T3 and intestinal epithelial cells with
different agonists (such as bombesin, lysophosphatidic acid, epidermal growth
factor (EGF) and platelet-derived growth factor (PDGF) can induce FAK-S910
phosphorylation through GPCRs or RTKs. (Hunger-Glaser et al., 2004; HungerGlaser et al., 2003; Jiang et al., 2007) Both types of receptors can transmit
downstream signals to activate ERK1/2, and ERK2 can directly phosphorylate
FAK at S910 in vitro.(Hunger-Glaser et al., 2003) The FAK-S910 residue also
can be directly phosphorylated by ERK5 and dephosphorylated by PP1δ in
breast cancer cells.(Villa-Moruzzi, 2007) FAK-S910 to alanine significantly
increased the interaction between paxillin and FAK. (Hunger-Glaser et al., 2003)
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This suggests that FAK-S910 phosphorylation might be important in regulating
the assembly of a larger signaling complex. Other studies have also shown that
FAK-S910 phosphorylation is important in cancer cell migration, invasion and
metastasis. Activated Ras can activate an Fgd1-Cdc42-PAK1-MEK1-ERK
signaling pathway, and activated ERK phosphorylates FAK at the S910 residue.
FAK-S910 phosphorylation creates a binding motif for PIN1 (protein interacting
with NIMA (never in mitosis A)) which recruits protein-tyrosine phosphatasePEST (PTP-PEST) to the complex. This interaction dephosphorylates FAK at
Y397 and subsequently inhibits FAK activity.(Li et al., 2010; Zheng et al., 2009)

Figure1: FAK domain structure and phosphorylation sites.
FAK and Pyk2 share a similar domain arrangement, with 42% sequence identity in FERM domain, 60%
sequence identity in Kinase domain and 39% sequence identity in C-terminal domain. Both proteins also have
identical tyrosine(Y, red) phosphorylation sites. FAK Y397, 576, 577 and 925 correspond to PYK2 Y402, 549, 580
and 811. FAK also contains several other serine(S, green), threonine (T, blue) and tyrosine phsohorylation sites, as
indicated in figure.
Beside its kinase function, FAK also serves as a scaffold protein. The FERM domain is important for signal
integration from growth factor receptors such as the Eph-family, EGF, and PDGF receptor PTKs. It also interacts with
scaffolding proteins such as JSAP1 and ezrin. The C-terminal FAT domain promotes FAK localization to focal
adhesions via associations with paxillin and talin. It is also responsible for RhoGTPase activation via interactions
withp190RhoGEF. Proline-rich motifs are found in both the N-terminal and C-terminal domains of FAK and these are
binding sites for SH3-containing proteins such as, p130Cas, Graf, andASAP1.FAK Y397 phosphorylation creates
high-affinitySH2binding sites for Src-family PTKs and the Shc adaptor protein whereas FAK Y925 phosphorylation
promotes the SH2-mediated binding of the Grb2 adaptor protein.FIP200 binding to the FAK kinase domain can inhibit
FAK catalytic activity.
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Figure 2: Model of FAK activation.

The FERM domain binds directly to the kinase C-lobe when FAK is auto-inhibited,
impeding access to the active site and protecting FAK's activation loop from
phosphorylation by Src. FAK is activated when it is released from the autoinhibited 'closed' state by the binding of a protein or lipid partner to its FERM
domain. Binding of partners to regions in the F1 or F2 subdomains of the FERM
domain is likely to 'open' the protein, permitting auto-phosphorylation and Src
binding. This leads to Src-mediated Tyr phosphorylation of the acceptor Tyr
residues in the kinase loop of FAK and full catalytic activation. FERM partners
may also serve to recruit FAK to larger protein complexes at specific subcellular
locations. (Modified from (Frame et al., 2010))
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9. FAK in cardiac hypertrophy
FAK is highly expressed in cardiomyocytes, and recent studies have
suggested that it is important in cardiac development, and biomechanical and
neurohumorally induced cardiomyocyte hypertrophy. FAK is involved in the
regulation of β-myosin heavy chain (β-MHC) and atrial natriuretic factor (ANF)
gene transcription in response to both mechanical load and the peptide growth
factor ET-1(Eble et al., 2000a; Eble et al., 2000b). Alternatively, adenoviral
overexpression of FRNK inhibited FAK-dependent signaling in neonatal rat
ventricular myocytes (NRVMs) and markedly suppressed NRVM hypertrophy
induced by ET-1 and PE.(Pham et al., 2000; Taylor et al., 2000) Knocking down
FAK by RNA interference also attenuated load-induced cardiomyocyte
hypertrophy,

β-MHC

expression,

fibrosis,

collagen

content

and

matrix

metalloproteinase-2 activity. (Clemente et al., 2007)
In 1995, Ilic and co-workers were the first to describe the effects of global
FAK deletion on early embryogenesis.(Ilic et al., 1995) These FAK knockout (KO)
mice displayed a major defect in axial mesodermal tissue development, and
development of the cardiovascular system. Normal heart development was
severely impaired, as was the development of blood vessels, leading to
embryonic lethality at E8.5. As the global FAK KO results in embryonic lethality, it
is therefore difficult to study the role of FAK in cardiac development and cardiac
hypertrophy.(Furuta et al., 1995; Ilic et al., 1995) Subsequently, two different
groups have generated mice containing ‘floxed’ FAK alleles, and have used
these animals to generate cardiomyocyte-specific FAK KO mice. This was
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accomplished by crossing the floxed FAK mice with either MLC2a-Cre or MLC2vCre mice to generate cardiac-restricted FAK KO mice.
In the MLC2v-Cre model, animals were viable, with normal cardiac
dimensions and normal ventricular function in the first 8 weeks of postnatal life.
Between 4 and 14 months of age, these ventricular-restricted FAK KO mice
developed a decrease in LV posterior wall thickness and an increase in interstitial
fibrosis in comparison to age-matched controls. After transverse aortic coarcation
(TAC), LV posterior wall thickness was not increased and hypertrophic gene
expression was attenuated in FAK KO mice but not in wildtype mice. These
results suggested that FAK is critical for the development of compensatory
hypertrophy in vivo.(DiMichele et al., 2006) In the other FAK MLC2vCre KO
mouse study, Peng et al. (Peng et al., 2006) showed that LV chamber
dimensions were significantly increased during both systole and diastole in FAK
KO mice compared with control mice when challenged by AngII stimulation or
TAC. In addition to the chamber dilation, the ratio of heart to body weight, and
heart weight/tibia length was also significantly increased in ventricular-restricted
FAK KO mice compared with control mice. Furthermore, the expression of
several hypertrophic markers, such as ANF, brain natriuretic peptide (BNP), βMHC and skeletal muscle α-actin (SK-actin) were increased in ventricularrestricted FAK KO mice as compared to control mice.(Peng et al., 2006) These
studies have shown the FAK KO mice develop different types of hypertrophy and
the difference between studies may be attributable to the difference in the timing
of FAK deletion, the extent of TAC and/or the genetic background of the mice.
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In the MLC2vCre FAK mouse model, the deletion efficiency in embryonic
heart was not complete, and therefore the role of FAK in cardiac development
was unclear. Peng et al. then created the MLC2aCre cardiac ventricle-restricted
FAK KO mice. In this model, the majority of the mice died in utero, with thin
ventricular walls and ventricular septal defects. A small fraction of KO mice
survived but these mice developed spontaneous eccentric right ventricular
hypertrophy.(Peng et al., 2008) Another restricted FAK KO mouse was
developed using an nkx2.5-Cre cross. Nkx2.5 is expressed during midgestation,
so that the FAK deletion occurred very early in cardiac development. The authors
showed that FAK is essential for appropriate ventricular septation and outflow
tract alignment. Of particular interest, the defects observed in these FAK
knockout hearts resemble some of the most common congenital malformations in
humans.(Hakim et al., 2007) Overall, these conditional KO mice studies indicate
that FAK is important in cardiac development and remodeling.

10. FAK in hypertrophic signaling
FAK can be activated though integrins, growth factor receptors, and
GPCRs leading to the activation of signaling pathways that regulate the
proliferation, migration, and survival of numerous cell types. Previous studies
have shown that different neurohumoral factors or mechanical stimulation can
induce a rapid increase in tyrosine phosphorylation of cardiomyocyte FAK. These
hypertrophich stimuli include phenylephrine (PE) (Taylor et al., 2000), ET-1(Eble
et al., 2000b), AngII (Browe and Baumgarten, 2004), and mechanical

25
stretch.(Domingos et al., 2002; Eble et al., 2000a; Seko et al., 1999) When FAK
is activated, it can form a FAK-Src signalling complex and activate downstream
signalling pathways. Studies have shown that several hyertrophic stimuli that
induced ERK1/2 activation also required upstream activation of FAK.(Domingos
et al., 2002; Seko et al., 1999) Recently, studies have also demonstrated that the
ERK1/2 signaling pathway can regulate the balance between eccentric and
concentric growth of heart.(Kehat et al., 2011) Furthermore the ERK1/2 signaling
cascade is involved in regulating fetal gene expression (e.g., ANF, β-MHC and
SK-actin). FAK also regulates the JNK and p38 pathways, which in turn have a
key role in the early activation of the hypertrophic genetic program by mechanical
stress in cardiomyocytes.(Aikawa et al., 2002; Nadruz et al., 2005) However, Lai
et al have shown that FAK is not involved in stretch-induced JNK and p38MAPK
activation.(Lal et al., 2007) The significance of FAK in regulating p38MAPK and
JNK is still contradictory.
In addition to the MAPK cascades, several studies have been proposed
that mTOR is also regulated by FAK. Activation of FAK leads to its increased
association with the p85 regulatory subunit of PI3K, and to concomitant activation
of AKT.(Del Re et al., 2008; Marin et al., 2008) Overexpression of constitutively
active AKT increased cardiomyocyte size, and this process could be attenuated
by rapamycin, an inhibitor of mTOR. Furthermore, several adaptor proteins, such
as p130Cas and paxillin, which have been implicated in the regulation of
cardiomyocyte function, are also regulated by FAK. Overall, these studies
indicate that FAK is critical in regulating specific hypertrophic signal transduction
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pathways.

11. FAK in Sarcomerogenesis and Myofibrillogenesis
In differentiated muscle, FAK is localized at the sarcolemma and
myotendous junction of skeletal myofibers in vivo (Baker et al., 1994; Fluck et al.,
2002) and it is also present in costameres in the intact heart in vivo.(Domingos et
al., 2002) In cultured cardiomyocytes, FAK is present at focal adhesion sites and
costameres. Cardiomyocyte-restricted deletion of FAK caused a dilated
cardiomyopathy with aging, and produced eccentric rather than concentric left
ventricular hypertrophy upon stimulation with AngII or transverse aortic
coarctation. In FAK KO mice, cardiomyocytes showed disorganized myofibrils
with increased nonmyofibrillar space filled by swelled and disorganized
mitochondria, and with additional structural changes at the intercalated disk.
These studies suggest that FAK is important in cell-cell interactions and myofibril
organization in cardiomyocytes.(Peng et al., 2006; Peng et al., 2008)
FAK phosphorylation is increased during skeletal and cardiac muscle
hypertrophy, which is associated with increased myofibrillar content in vivo and in
vitro.(Carson and Wei, 2000; Eble et al., 2000b; Fluck et al., 1999; KovacicMilivojevic et al., 2001; Laser et al., 2000; Taylor et al., 2000) Several studies
have shown that impeding cardiomyoycte FAK phosphorylation by different
stimuli (i.e. oleic acid, 17β-estradiol and 5α-dihydrotestosterone) can interfere
with normal sarcomeric structure.(Huang et al., 2007; Koshman et al., 2009)
Previous studies from our lab have demonstrated that FAK overexpression alone
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is not sufficient, in the absence of other hypertrophic stimuli, to promote
sarcomeric assembly. Overexpression of FRNK in cardiomyocytes prevents ET-1
induced increase in protein-to-DNA ratio, and the assembly of newly synthesized
myofibrillar proteins into sarcomeres.(Eble et al., 2000b) Kovacic Milivojevic et al.
have also found that overexpression of the FAK FAT domain in cardiomyocytes
disrupted sarcomere structure. When cardiomyoctes overexpressed the FAT
domain, the Z-line marker α-actinin or A-band marker β-MHC were diffusely
distributed in the cytoplasm, or concentrated in dense granules. Additionally, the
focal adhesion marker tensin in control cells was not only present at focal
adhesions and fibrillar adhesions, but also at the Z-line. But in FAT
overexpressing myocytes, cells started losing tensin staining in focal adhesions
and Z-lines.(Kovacic-Milivojevic et al., 2002; Kovacic-Milivojevic et al., 2001) In
response to mechanical stimulation, cardiomyocytes can add approximately one
sarcomere per hour and effectively compensate for an increase in resting
sarcomere length. Exchange of endogenous FAK with FRNK subsequently
prevented the recovery of resting sarcomere length following mechanical
stimulation.(Mansour et al., 2004)
FAK also plays an important role in normal costamerogenesis and normal
myofibrillogenesis during skeletal muscle differentiation. Overexpression of the
FAK FAT domain diminished FAK Y397 phosphorylation, but did not change the
expression level of a differentiation-specific marker (i.e., MHC and α-actinin).
Knocking down FAK with siRNA or overexpressing the FAK FAT domain both
significantly reduced costamerogenesis and myofibrillogenesis.(Quach and
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Rando, 2006) These findings suggest that FAK is required for the normal
assembly of costameres or myofibrils in both cardiac and skeletal muscle.

12. FAK FAT domain conformation
The C-terminal domain of FAK contains the FAT domain, which is
necessary and sufficient for localizing FAK to focal adhesions. From its X-ray
crystal structure, the FAT domain is organized into a four-helix bundle (H1-H4),
and the helices are straight and closely anti-parallel. Each helix is connected by
short loops, forming a highly compact, symmetric bundle with a square crosssection. All four helices can interact with each other through the hydrophobic
residues within each helix.(Hayashi et al., 2002b) Arold et al. have shown that
the FAT domain can form two different forms during crystallization. One of the
crystal forms contains helix-exchanged dimers in which H1 is swapped. NMR
studies have also shown that residues at the C-terminus of H1, Loop 1 and Nterminal of H2 display line broadening suggesting that this region may be subject
to conformational exchange in solution.(Arold et al., 2002) Furthermore, in a
scaled GÖ model simulation study, investigators showed that a folding
intermediate ensemble mat exist in which H1 is less structured and separated
from the helix bundle. From these studies, it can be concluded that the structure
of the FAT domain probably reflects the ability of FAK to undergo a dynamic
conformational change (i.e., an open or closed conformation) as FAK exchanges
between the focal adhesions and cytoplasm.(Arold et al., 2002; Dixon et al., 2004;
Prutzman et al., 2004)
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The FAT domain interacts with several different proteins, including talin
and paxillin.(Chen et al., 1995; Hildebrand et al., 1995) The interaction between
FAT and paxillin is necessary but not sufficient for localization of FAK to focal
adhesions.(Cooley et al., 2000) The paxillin binding site (PBS) of FAK is located
at 919-1042, which closely matches the limits of the ordered domain. The FAT
domain contains two hydrophobic patches, and mutation at I936E/I988E in which
both hydrophobic patches are mutated, completely abrogated paxillin binding.
Interestingly, paxillin interacts with the FAT domain through its LD2 and LD4
motifs within the N-terminal region of paxillin and either one of the LD motifs can
directly bind to the FAK FAT domain. Recent studies indicate that paxillin binds
to the FAT domain at interfaces between H1 and H4, as well as between H2 and
H3. Moreover, paxillin can only interact with FAK displaying a rigid four-helix
bundle conformation (close conformation), but not with FAK displaying significant
structural rearrangements (i.e., the open conformation).(Gao et al., 2004;
Hoellerer et al., 2003; Liu et al., 2002a). Paxillin and FAK interaction can
enhance the interaction between H1 and H4, and appears to further stabilize the
structure of FAT domain.(Liu et al., 2002a)
H1 contains one tyrosine phosphorylation site (Y925), which can be
phosphorylated by integrin clustering and different agonists. (Heidkamp et al.,
2003; Schlaepfer et al., 1998) The solution structure of the FAT domain has
shown that Y925 is only partially exposed to the solvent, and Y925 is also
partially covered by the bound LD2 peptide in the structure of the FAT-LD2
peptide complex. Therefore, paxillin binding might be interfered with by Y925

phosphorylation,

but

additional

evidence

indicates

that

FAK
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phosphorylation and GRB2 binding require that the FAT conformation switch
between the closed and open conformations.(Figure 3) (Arold et al., 2002; Dixon
et al., 2004; Prutzman et al., 2004) Therefore, this FAT domain conformational
change could facilitate FAK dissociation from the focal adhesion complex, and
promote GRB2 activation of the MAPK pathway.

13. Concluding remarks.
Previous studies have shown that FAK can be serine-phosphorylated in
several different cell types, but only one paper has addressed the role of FAK
serine phosphorylation in an animal model of cardiac hypertrophy and heart
failure. Thus, FAK serine phosphorylation and its regulation and function in the
cardiomyocyte remain unknown. The objectives of this dissertation were to
characterize FAK serine phosphorylation in cultured NRVM and in nonfailing and
failing human LV tissues, and to analyze its functional significance during
hypertrophic signaling. To this end, I have used a variety of experimental
approaches and a combination of experimental techniques to analyze the
regulation and function of FAK serine phosphorylation in cardiomyocytes.
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Figure 3. Working Model for the Biological Role of the Open and Closed
Forms of the FAT Domain: (A and B) Contact with the ECM stimulates integrin
clustering and the formation of focal adhesions (FAs), which in turn promote
recruitment of FAK to FAs. In the closed form, the FAT domain binds paxillin and
localizes full-length FAK to focal adhesions. The FAT domain can also adopt an
open conformation, which disrupts paxillin binding and enables Src kinases to
phosphorylate Y926. Phosphorylation of Y926 creates a recognition site forGrb2,
which activates ERK/MAPK signaling. Phosphorylation of Y926 also leads to the
exclusion of FAK from focal adhesions, one possible mechanism for terminating
FAK signaling and promoting focal adhesion turnover in migrating cells.(Dixon et
al., 2004)

CHAPTER TWO
Materials and Methods
1. Reagents for cell culture
PC-1TM complete medium was purchased from Lonza (Walkersville, MD)
and medium 199 (M199) medium were from Invitrogen (Carlsbad, CA). (Ca2+-free
and Mg2+-free Hanks' balanced salt solution (HBSS), acid-soluble calf skin
collagen, and antibiotic/antimycotic solutions were obtained from Sigma
Chemical (St. Louis, MO). Type II collagenase was purchased from Worthington
(Lakewood, NJ), and DMEM and penicillin–streptomycin were obtained from
Fisher Scientific/MediaTech (Itasca, IL).
2. Cell isolation
Animals used in these experiments were handled in accordance with the
Guiding Principles in the Care and Use of Laboratory Animals, published by the
US National Institutes of Health and approved by the American Physiological
Society. The animal protocol was approved by the Institutional Animal Care and
Use Committee of Loyola University Medical Center. NRVM isolation was
described.(Samarel and Engelmann, 1991) Neonatal rat pups, at postnatal day 1
to 2 were decapitated and the heads were immediately frozen in liquid nitrogen to
lessen pain. Bodies were washed with 1% betadine and the chest cavity was
opened to expose the heart. The fresh hearts were rapidly removed and placed
32
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into Petri dishes containing fresh perfusion buffer.
Atria and major blood vessels were removed from freshly isolated hearts
and minced with a clean, unused razor blade. About 10 hearts were placed into
each 25ml Erlenmeyer flask containing 10ml of perfusion buffer with 0.3mg/ml
collagenase. Minced hearts were incubated with shaking at 100-1200 rpm for
15min at 37°C. The supernate from the first and second digestions were
aspirated off and discarded. Fresh collagenase solution was added and
incubated for 22 min. With about 8 min remaining, flasks were quickly removed,
and the tissue fragments were resuspended with a transfer pipette about 10
times. After 22 min incubation, tissue fragments were allowed to settle by gravity
and the supernate was collected using a transfer pipette. The supernate was
filtered through a sterile 40µm nylon filter and washed with 3ml of enzyme-free
buffer. The same procedure was repeated two more times. The cells released
from each digestion were isolated by centrifugation and each pellet was
resuspended with 10ml of enzyme-free perfusion buffer containing 5mM EDTA
into a 50ml collection tube. After the final collection, the collection tube was
centrifuged at 1000-1500rpm for 8min. The pellets were resuspended in 20ml of
PC-1 medium, and 10ml each was placed into a T-75 flask for differential plating.
After 30min, the medium containing unattached cells (predominantly myocytes)
was gently removed from the flasks to 50ml tubes without disturbing the attached
cells (predominantly fibroblasts and endothelial cells). Each flask was rinsed with
10ml of PC-1 medium and carefully rocked without disturbing the attached cells.
The supernate were removed and all of the media were combined. The cells
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were gently mixed with a plastic transfer pipette and counted with a
hemocytometer.

3. Cell Culture
NRVM were plated in PC-1 medium onto collagen-coated 35mm dishes or
fibronectin-coated chamber slides for 24hr. Unattached NRVM were removed by
aspiration,

and

the

attached

myocytes

were

switched

to

serum-free,

DMEM/Medium 199 (4:1) containing antibiotic/antimycotic solution. NRVM were
either treated with drugs or infected with replication-defective adenoviruses for
varying time periods (24-72h).

4. Human tissue samples
Samples of LV tissue were obtained from Loyola University Medical
Center’s (LUMC’s) Cardiovascular Institute Tissue and Blood Repository, and
from the Gift of Hope Organ and Tissue Donor Network. The investigation
conformed to the principles outlined in the Declaration of Helsinki. A detailed
protocol and informed consent document were reviewed by LUMC’s Institutional
Review Board prior to tissue procurement. Following informed consent,
explanted human LV tissue was obtained from patients undergoing heart
transplantation for nonischemic, dilated cardiomyopathy (DCM). Tissue samples
were quick-frozen in liquid N2 in the operating room and stored at -80oC.
Following informed consent from organ donor family members, donor hearts
judged unsuitable for cardiac transplantation were stored in cardioplegic solution
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on ice and were delivered within ~4h of cardiac extirpation by the Gift of Hope
Organ and Tissue Donor Network. Tissue samples were then quickly frozen in
liquid N2, and stored at -80oC.

5. Reagent for Molecular Assay
Restriction enzymes, DNA ligase, Klenow Fragment (3´→5´ exo-), dNTP,
NEB 10-β Competent E. coli (High Efficiency) and 1kbp and 100bp ladders were
obtained from New England Biolabs, Inc. (Ipswich, MA). Agarose was purchased
from Amresco (Solon, OH). shRNA oligonucleotides were

synthesized by

Integrated DNA technologies (Coralville, Iowa). QIAEX II Gel Extraction Kits and
Qiagen plasmid Maxi kits were obtained from Qiagen (Valencia, CA).

6. Reagent for Biochemical Assay
Phospho-Y397, -S722, -S732 and -S910 FAK rabbit polyclonal antibodies
(pAbs) were obtained from Invitrogen and Phospho-S843 FAK pAb was obtained
from Abcam (Cambridge, MA). Phospho-Y925 FAK, Phospho-Y311, T505, S643
PKCδ, Phospho-T218/Y220 ERK5 and ERK5 pAbs were purchased from Cell
Signaling Technology (Beverly, MA). Anti-active MAPK pAb was obtained from
Promega. ERK2 (C-14), C-Src (Src2) pAb were obtained from Santa Cruz
Biotechnology Inc (Santa Cruz, CA). FLAG pAb, vinculin monoclonal antibody
(mAb0 and α-actinin mAb were purchased form Sigma Chemical Co., (St. Louis,
MO). Anti-GAPDH mouse mAb was purchased from Novus Biologicals (Littleton,
CO). mAbs to FAK, Paxillin, PKCε, PKCδ and PKCα were obtained from BD
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Transduction Laboratories (Sparks, MD). Rhodamine-phalloidin was purchase
from Invitrogen (Eugene, OR). Goat-anti-rabbit and goat-anti-mouse secondary
Abs were obtained from Bio-Rad (Hercules, CA) and FITC-conjugated goat-antirabbit and rhodamine-conjugated goat-anti-mouse secondary Abs were obtained
from Invitrogen. BQ610, GF109203X, GÖ6983, phorbol-12-myristate-13-acetate
(PMA), PD98059, PD142893, PP2, PP3, Rottlerin, SB203580 and U0126 were
purchased from EMD Chemicals (Gibbstown, NJ). Sorafenib was obtained from
LC Laboratories (Woburn, MA). PF573228 was purchase from Tocris (Ellisville,
MO). BCA Protein Assay kit was purchased from Thermo Fisher Scientific
(Waltham, MA) All other reagents were of the highest grade commercially
available and were obtained from Sigma.

7. Bacterial transformation
For DNA amplification, plasmids were transformed into NEB 10-β
Competent E. coli (High Efficiency). 10-β bacteria were removed from -80°C and
placed on ice until thawed. Competent cells (50 µl) were placed into a clean
chilled Eppendorf tube. 100ng DNA was slowly added to the thawed bacteria.
After incubating on ice for 30min, the cells was heat shocked at 42°C for 15 sec,
and placed on ice for 5 min. Then 550 µl sterile LB broth was added into the tube
and shocked at 37°C, 250 rpm for 1 h. Finally the bacteria were spread out on
agar plate that contained ampicillin (100µg/ml) or kanamycin (50µg/ml) and
incubated in a 37°C incubator for 14-16 h. A single colony was picked and
transferred into a 15 ml tube that contained 3 ml ampicillin or kanamycin LB broth.
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The culture was shocked at 37°C, 250 rpm for 14-16 h.

8. Plasmid isolation: Small scale plasmid preparation
2ml overnight cultures were centrifuged at 16,000g for 3 min and the
supernatant fractions were removed. The pellets were resuspended in 100 µl P1
buffer (50 mM Tris-HCl pH 8.0, 10 mM EDTA and 100 µg/ml RNase A) and then
100 µl of P2 buffer (200 mM NaOH and 1% SDS) was added. The tubes were
mixed by vigorously inverting 4-6 times, and then incubated at room temperature
for 5 min. After addition of 100 µl of P3 buffer (3M potassium acetate pH 5.5), the
tubes were immediately mixed and incubated on ice for 5 min. The tubes were
then centrifuged at 16,000g for 10 min at 4°C. After centrifugation, the
supernates were removed to a clean tube and 2-2.5x volume of 99.5% ethanol
was added. The mixtures were centrifuged at 16,000 g for 10 min at 4°C and the
supernates were aspirated. The DNA pellet was washed with 70% ethanol and
centrifuged again. The supernates were discarded and the pellets were dissolved
in TE buffer.

9. Plasmid Isolation: Large scale plasmid preparation
After analysis of the small-scale plasmid preparations, positive colonies
were cultured in 200 ml LB at 37°C. The bacteria were pelleted by centrifugation,
and the plasmids were purified using the QIAGEN Maxi-Prep Plasmid Purification
Kit, according to the manufacturer’s instructions. The purified DNA pellet was
dissolved in TE buffer and stored at -20°C.

38
10. Site-directed mutagenesis
3xFlag-WT-FAK plasmid was kindly provided by Dr. Joseph C. Loftus,
Mayo Clinic Arizona. The phospho-dead mutation or phospho-mimic mutation
was

performed

by

USB

Change-ITTM

Multiple

Mutation

Site

Directed

Mutagenesis Kit (Santa Clara, CA). The primers used for mutagenesis were
designed as follow: 5’-/phos/ CTT-CAG-CCC-CAG-GAA-ATC-GCC-CCC-CCTCCC-ACT-GCC-AAC-3’ for S910A, 5’-/phos/ CTT-CAG-CCC-CAG-GAA-ATCGAC-CCC-CCT-CCC-ACT-GCC-AAC-3’

for

S910D,

where

the

underline

represent the mutated bases. The primers were synthesized by Integrated DNA
Technologies (Coralville, IA). 3x-Flag-WT-FAK (15ng) was used as template and
mixed with other reagents as described in the table below:

Final
concentration

Component

Volume (µl)

10X Change-ITTM Buffer

2.0

1X

5M Phosphorylated Mutagenic Primer

1.0

0.25M

5M Amp REV Primer

1.0

0.25M

3xFlag WT-FAK

1.0

15ng

Nuclease-Free Water

14.2

NA

Change-ITTM Enzyme

0.8

NA

Phosphorylated primers were annealed to each strand of the plasmid
template. FideliTaqTM DNA Polymerase extends from each primer until the
phosphorylated 5'-end of either the original or other primer is encountered.
Thermostable ligase joins the DNA product(s) to create circular dsDNA. This
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dsDNA becomes the template for subsequent cycles of PCR amplification. The
cycle reaction was according to the following table:
Cycle name
Initial denature
Denature
35
Anneal
cycles
Extend
Final extension
Hold

Temperature
95°C
95°C
65°C
68°C
68°C
4°C

Time
2 min
30 sec
30 sec
18 min
10 min
NA

After the PCR, 10µl of reaction product was removed to a fresh tube and
1µl of DpnI was added to the tube, which was incubated at 37 °C for 2 h. The
DpnI digest reaction mixture was then transformed to NEB 10-β Competent E.
coli. The mutational results were confirmed by DNA sequencing.

11. Short Hairpin RNA expression vectors
The

pRNAT-H1.1/Adeno

vector

was

purchased

from

GeneScript

(Piscataway, NJ) and the siRNA sequences were design by GenScript siRNA
Construct Builder. Each siRNA sequence had a MluI site at the 5’ end and a
HindIII site at the 3’ end. The sequences for each target gene are shown in the
following table:
Gene
FAK-1Top
FAK-1Bot
FAK-2Top

Sequence
5’CGCGCGCAATGGAACGAGTATTAAATTCAAGAGATT
TAATACTCGTTCCATTGCATTTTTTGGAA-3’
5’AGCTTTTCCAAAAAATGCAATGGAACGAGTATTAAAT
CTCTTGAATTTAATACTCGTTTCCATTGCG-3’
5’CGCGCGCCACCTGGGCCAGTATTATTTCAAGAGAAT
AATACTGGCCCAGGTGGTTTTTTGGAAA-3’

Location

94-112 (Rattus)
94-112 (Mus)

146-166 (Rattus)
146-166 (Mus)
146-166 (Homo)
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FAK-2Bot

5’AGCTTTTCCAAAAAACCACCTGGGCCAGTATTATTCT
CTTGAAATAATACTGGCCCAGGTGGCG-3’

Pyk2-1Top

5'CGCGGATGTAGTTCTTAACCGCATTCAAGAGATGCG
GTTAAGAACTACATCTTTTTT-3'

Pyk2-1Bot

5’AGCTAAAAAAGATGTAGTTCTTAACCGCATCTCTTGA
ATGCGGTTAAGAACTACATC-3’
5'CGCGGATGCTTGGACCCGATGGTTTCAAGAGAACC
ATCGGGTCCAAGCATCTTTTTT-3'
5'AGCTAAAAAAGATGCTTGGACCCGATGGTTCTCTTG
AAACCATCGGGTCCAAGCATC -3’
5'CGCGCGGTGCTGAAGGTTCGAGACTTCAAGAGAGT
CTCGAACCTTCAGCACCTTTTTTGAAA-3'
5'AGCTTTTCCAAAAAAGGTGCTGAAGGTTCGAGACTC
TCTTGAAGTCTCGAACCTTCAGCACCG-3'
5'CGCGCACAGACGCTCAGCAGACATTTCAAGAGAAT
GTCTGCTGAGCGTCTGTTTTTTTGGAAA-3'
5'AGCTTTTCCAAAAAAACAGACGCTCAGCAGACATTCT
CTTGAAATGTCTGCTGAGCGTCTGTG-3`
5'CGCGTACGCGGAATACTTCGATTCTCAAGAGAAATC
GAAGTATTCCGCGTACGTTTTTT-3'
5'AGCTAAAAAACGTACGCGAATACTTCGATTTCTCTTG
AGAATCGAAGTATTCCGCGTA-3'

Pyk2-2Top
Pyk2-2Bot
ILK-1Top
ILK-1Bot
ILK-2Top
ILK-2

Bot

Luc-1Top
Luc-2bottom

1269-1287 (Rattus)

2479-2497 (Rattus)

723-741 (Rattus)
695-713 (Mus)
728-746 (Homo)

1169-1187 (Rattus)
1281-1299 (Mus)
1287-1305 (Homo)

The oligos were PAGE-purified and dissolved in water to 1µg/µl. Top and
bottom oligos (1µg) were mixed in annealing buffer (1xSSC) and boiled at 95°C
for 10 min. The mixture was put at room temperature for one hour and the
mixture was diluted to a final concentration of 40ng/µl. The annealed oligos were
subcloned into pRNAT-H1.1/Adeno vector. The results were confirmed by DNA
sequencing.
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12. Adenoviral constructs
Replication-defective adenoviruses encoding constitutively active (ca)
PKCδ (Adv-caPKCδ) and dominant-negative (dn)PKCε (Adv-dnPKCε) were
constructed as previously described.(Eble et al., 1998) dnPKCε adenovirus was
kindly provided by Dr. Peipei Ping, University of California-Los Angeles. caMEK5
and dnERK5 adenoviruses were kindly provided by Dr. Jun-ichi Abe, University
of Rochester. YFP-α-actinin adenovirus was kindly provided by Dr. Joseph W
Sanger, Upstate Medical University. dnSrc (K295R, Y527F double mutant)
plasmid was constructed by Dr. Joan Brugge, and was purchased from Addgene
(Plasmid #13657; Cambridge, MA) (Figure 5). dnFyn (K295R, Y527F double
mutant) plasmid was constructed by Dr. FG Giancotti, and was purchased from
Addgene (Plasmid #16033; Cambridge, MA) (Figure 4). A replication-deficient
Adv expressing GFP-paxillin was kindly provided by Dr. Mark Sussman, San
Diego State University. 3xFlag-WT-FAK, 3XFlag-S910A-FAK, and 3XFlagS910D-FAK adenoviruses were constructed by subcloning pShuttle-CMV vector
(Figure 6) using SnaBI and XbaI. dnSrc was subcloned into pShuttle-CMV vector
by using Hind III. dnFyn was subcloned into pShuttle-CMV vector by using
BamHI.

13. Adenoviral preparation
Once constructed, the shuttle vector was linearized with Pme I and
transformed into BJ5183-AD-1 electroporation-competent cells using an
electroporator (200Ω, 2.5kV, 25µF). Recombinant adenovirus plasmid was
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screened by Pac I digestion. If successful recombination occurs, the recombinant
adenovirus plasmid DNA following Pac I digestion should yield fragment larger
than 30kb, and a smaller fragment of either 3.0kb or 4.5kb. The recombinant
adenovirus plasmid was transformed into NEB 10-β Competent E. coli and
screened with Pac I.
Recombinant adenovirus plasmids were digested with Pac I for 2h and
precipitated by ethanol precipitation. The Pac I-digested recombinant adenovirus
plasmid was then transfected into 70% confluent AD-293 cells using Xfect™
Transfection Reagent (Clontech). After 16 h, the medium was removed and
changed to fresh medium. After approximately 14 days, plaques containing
cytopathic effects (CPEs) began to form in the confluent monolayer. Once CPEs
were detected, cells were lysed by freeze/thaw twice and centrifuged. The
supernate was used to infect additional AD-293 cells for further viral amplification.
At same time, AD-293 cells were plate onto 10-15 15cm dishes. Once the
cells were ~70% confluent, each dish was then infected with 2ml of viral stock
solution. Cells were incubated for another 48-72 h until CPEs were visible by
phase-contrast microcsopy.

Cells were then washed off the plate surface,

pelleted by centrifugation, and resuspended in 5ml DMEM with 10% FBS. The
virus was extracted by doing two freeze/thaw cycles, and the virus was purified
by cesium chloride gradient centrifugation. The gradient purification was
conducted by first pipetting 5 ml of CsCl 1.2 (26.8g+92ml of 10mM Tris-HCl, pH
7.9) and then carfully loading a 3 ml cushion of CsCl 1.4 (53g+97ml of 10mM
Tris-HCl, pH 7.9) into the bottom of the tube without disturbing the top layer. Up
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to 4ml of virus particles were carefully loaded onto the top of the gradient. The
tubes were then centrifuged at 100,000g for 2 h at 16°C. The virus particles were
collected by using a 21g needle to puncture the side of tube at the lower bluishwhite band. The virus particles were injected into a Slide-A-Lyzer Dialysis
Cassette (10kDa molecular weight cutoff) and dialyzed in dialysis buffer at 4°C
overnight to remove the CsCl. The virus particles were then maintained in 10%
glycerol at -80°C.

14. Flexercell stretch system
NRVM were plate in PC-1 medium onto collagen-coated 6 well Bioflex
stretch plates. Static stretch was produce with a Flexercell strain Unit (Model FX3000, Flexercell International, McKeesport, PA) at 20% strain for various time
periods. The Flexercell strain unit consists of a vacuum manifold regulated by
solenoid valves that is controlled by a personal computer. The percentage of
strain is defined by the membrane percentage of elongation (% of strain). All
experiments were performed using 20% static or cyclic stretch. NRVM were
stretched for varying time periods (5 to 60 min) with no significant cell damage.

15. Co-immunoprecipitation
NRVM were infected (10moi, 48h) with Adv-WT-FAK or Adv-S910A-FAK
and then treated with ET-1 for 1h. For co-immunoprecipitation, cells were
washed twice with phosphate-buffered saline and lysed on ice with 200µl of nondenaturing lysis buffer (20mM Tris-HCl, pH 8, 137mM NaCl, 0.25%, 1% Nonidet
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P-40, 2 mM EDTA and 10% glycerol) supplemented with 1mM PEFABloc,
10µg/ml leupeptin, 500µM vanadate and 10µg/ml aprotinin. The cell lysates were
freeze-thawed twice in liquid nitrogen, and were then centrifuged (16,000×g;
15min). The supernates were collected and protein concentration was measured
by BCA assay. Cell lysates (1000µg of total protein) were pre-cleaned with 60µl
Protein A/G beads (1h, 4°C) and centrifuged (2,500×g; 3 min). The supernates
were incubated with 2µg antibody (FLAG, paxillin or vinculin) at 4°C on a rocker
platform overnight and then 50µl Protein A/G beads was added for 4h. The
beads were centrifuged (2,500×g; 3min), the supernatant discarded, and the
beads were washed three times with 1 ml cold non-denaturing lysis buffer. The
beads were then resuspended in 200µl of SDS-PAGE sample buffer and heated
to 95°C for 10 min. The beads were centrifuged (10,000×g; 3 min) and the
supernatant used for SDS-PAGE and immunoblot analysis.

16. Sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE)
NRVM were washed twice with ice-cold PBS and sonicated in lysis buffer
containing 1% Triton X-100 and 0.1% SDS supplemented with 1 mM PEFABloc,
10 µg/ml leupeptin, 500 µM vanadate and 10 µg/ml aprotinnin. The cell lysates
were vortexed 4 times every 15 min and were then centrifuged for 15 min at
16,000 × g. The supernates were collected and protein concentrations were
measured by BCA assay. Equal amounts of extracted cellular proteins were
mixed with Laemmli sample buffer (62.5 mM Tris-HCl, pH6.8, 0.01%
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bromophenol blue, 8% SDS, 5% 2-mecaptoethanol and 10% glycerol) and
denatured by heating to 100°C for 10 min. Samples and protein markers were
loaded onto 6%, 8% or 10% SDS-polyacrylamide gels with 4% stacking gels,
depending on the molecular weight of the proteins of interest. The vertical gels
were run at constant current in running buffer (25 mM Tris-HCl, 192mM glycine
and 0.1% SDS). Samples were first run at 10 mA per gel until the bromophenol
blue tracking dye entered the separating gel, and then the current was increased
to 25 mA per gel. After the bromophenol blue tracking dye had reached the
bottom of the separating gel, the power supply was turned off and the gels were
prepared for immunoblotting.

17. Immunoblotting
After SDS-PAGE, the separated proteins were transferred to nitrocellulose
paper in transfer buffer (30mM Tris-HCl, 200mM glycine and 20% methanol) at
20mA overnight at 4°C (total current less then 5.5 mA/cm2). Blots were washed
twice with TBST (10 mM Tris-HCl, 0.05% Tween 20 and 150 mM NaCl pH 8.0)
and incubated with blocking solution (5% non-fat milk solids in TBST) for 1 h at
room temperature. Primary antibody solution was prepared by diluting antibody
according to optimal concentration (see table below) in blocking solution
overnight at 4 °C. After primary antibody incubation, the blots were washed 3
times in TBST for 5 min each. Secondary antibody solution was prepared by
diluting secondary antibody (goat-anti-mouse IgG conjugated with horsesadish
peroxidase at 1:5,000; and goat-anti-rabbit IgG conjugated with horsesadish
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peroxidase at 1:5,000) in blocking solution. The blots were incubated with
secondary antibody solution for 1 h at room temperature. The blots were then
washed 3 times in TBST for 5 min each. Antibody interaction was detected by
using Supersignal West Pico Chemiluminescent substrate (Thermo Scientific).
Band intensity was quantified using laser densitometry.
Antibody
ERK2 mAb
p-ERK1/2 pAb
p38 pAb
p-p38 pAb
ERK5 pAb
p-ERK5 pAb
FAK mAb
FAK S722 pAb
FAK S732 pAb
FAK S843 pAb
FAK-S910 pAb
FAK Y397 pAb
FAK Y861 pAb
FAK Y925 pAb
Paxillin mAb
Paxillin Y118 pAb
Hic-5 mAb
PKCα mAb
PKCε mAb
PKCδ mAb
PKCδ T505 pAb
PKCδ Y311 pAb
PKCδ S643 pAb
Talin mAb
Vinculin mAb
Flag pAb
c-Src mAb
Raf-1 mAb
GAPDH mAb
α-actinin II mAb

Supplier
Santa Cruz
Promega
Cell Signaling
Cell Signaling
Cell Signaling
Cell Signaling
BD Bioscience
Invitrogen
Invitrogen
Abcam
Invitrogen
Invitrogen
Invitrogen
Cell signaling
BD Bioscience
Cell Signaling
BD Bioscience
BD Bioscience
BD Bioscience
BD Bioscience
Cell Signaling
Cell Signaling
Cell Signaling
Sigma
Sigma
Sigma
Santa Cruz
BD Bioscience
Novus Biologicals

Sigma

Dilution
1:3000
1:3000
1:1000
1:1000
1:1000
1:1000
1:1000
1:1000
1:1000
1:1000
1:2000
1:1000
1:1000
1:1000
1:1000
1:1000
1:3000
1:1000
1:1000
1:2000
1:1000
1:1000
1:1000
1:1000
1:1000
1:3000
1:1000
1:1000
1:1500
1:2000
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18 Cell surface area measurements
NRVM were infected (10moi, 24h) with WT-FAK or S910A-FAK and then
treated with ET-1 100nM for 48h. Cells were then washed with modified Krebs
medium (135mM NaCl, 5.9mM KCl, 1.5mM CaCl2, 1.2mM MgCl2, 11.5mM
glucose, and 11.6mM HEPES, pH 7.3, supplemented with 0.1% BSA and 0.2%
Pluronic F-127 detergent) and loaded (1h) with 2′7′-bis (2-carboxyethyl)-5(6)carboxyfluorescein (BCECF)-AM (2 µM in modified Krebs medium), followed by
1h incubation in BCECF-free Krebs buffer.(Heidkamp et al., 2007) Cells were
viewed using an epifluorescence microscope (Zeiss) with 40×/0.8 NA (water)
apochromat 40× objective, and images were required with a digital camera
(AxioCam HR; Zeiss) running Axiovision AC V4.5 software. Digital images were
analyzed using ImageJ software (NIH, Bethesda, MD). JPEG images were
converted to binary images and adjusted for threshold brightness, which
distinguished the fluorescent cells from the black background. Cell area was
determined by particle analysis (size: pixel2 10000 - infinity) and more than 150
cells were measured for each experiment.

19 Total internal reflection fluorescence (TIRF)-microscopy
and fluorescence recovery after photobleaching (FRAP).
NRVM grown on 4-well borosilicate chamberslides coated with fibronectin
were infected with Adv-WT-FAK or Adv-S910A-FAK (10moi for 24h) and then
infected with Adv-YFP-α-actinin or Adv-GFP-paxillin (10moi) for another 24h.
Cells were imaged using an inverted TIRF-microscope. TIRF used the 457.9-nm
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Ar laser line, directed through the objective with a multiple band dichroic mirror
and emission was selected with a 542/27nm filter. For FRAP, the Argon laser
was directed to the sample with a 10/90 beam splitter mounted in a second filter
cube carousel positioned above the excitation dichroic. Bleach spot sizing was
accomplished with a Keplerian telescope mounted on an XYZ translation stage.
Laser photobleaching exposure time was controlled by Uniblitz shutters and was
typically 125 ms. The shutter events and stream acquisition was controlled by
acquisition software. A single peripheral FA in an individual cell (20 cells per
group) was randomly selected, and subjected to FRAP analysis. Fluorescence
intensity data were acquired every 25 ms for up to 16 sec after photobleaching a
small region of interest encompassing a single FA site.(Koshman et al., 2010a)
The intensity data immediately after the laser flash (F) were then normalized to
the initial fluorescence intensity (F0) and plotted as a function of time (sec). Data
were then fit to the following signal-exponential function:
F/F0 = Y0 + M1×(1-ek1×t)
where Y0 was the best-fitting value for F/F0 at t=0 (i.e., immediately after
the flash), kFRAP was the first-order rate constant (sec-1) describing the rate of rise
of F/F0 to plateau. The data were fit using SigmaStat Ver. 3.1 software.

20 Double-label immunofluorescent microscopy
NRVM grown on coverslips coated with fibronectin were infected (10moi,
24h) with Adv-WT-FAK or Adv-S910A-FAK. NRVM were then stimulated with ET1 (100nM) for 48h. Cells were fixed (2% paraformaldehyde in PBS; 15min),
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incubated to removed aldehydes (1% glycine in PBS, 15min), permeabilized
(0.5% Triton X-100 in PBS; 15min) and blocked (5% BSA in PBS; 1h). Cells were
incubated with anti-FLAG antibody (1:400) at 4°C. After overnight incubation, the
cells were washed with 0.1% Triton-X100 in phosphate-buffered saline, and
FITC-conjugated goat-anti-rabbit IgG was added for 2hr. Cells were then stained
with rhodamine-conjugated phalloidin (1:40 in PBS) for 30min to visualize F-actin
filaments and myofibrillar structure. Fluorescently-labeled cells were viewed
using an epifluorescence microscope (Zeiss) with 63×/1.45 NA (oil) planapochromat 63× objective, and images were acquired with a digital camera
(AxioCam HrM Zeiss) controlled by Axiovision AC V4.5 software.

20 Data analysis.
Results were expressed as means±S.E.M. Normality was assessed using
the Kolmogorov–Smirnov test, and homogeneity of variance was assessed using
Levene's test. Data were compared by 1-way ANOVA or 1-way ANOVA on
Ranks, followed by the Dunnett’s test or Student-Newman-Keuls test (multiple
groups); or unpaired t-test or Wilcoxin-Rank sum test (two groups), where
appropriate. Differences among means were considered significant at P<0.05.
Data were analyzed using the SigmaStat Statistical Software Package, Ver. 3.11
(Jandel Scientific, San Rafael, CA).
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Figure 4. pshCMV DnFyn map

Dn-Fyn plasmid was purchased from Addgene and then subcloned into pShuttle
CMV vector by using BamHI.
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Figure 5. pshCMV DnSrc map
Dn-Src plasmid was purchased from Addgene and then subcloned into pShuttleCMV vector by using Hind III.
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Figure 6. pshCMV 3xFlag-WT-FAK, 3XFlag-S910A-FAK, and 3XFlag-S910DFAK map

3xFlag-WT-FAK, 3XFlag-S910A-FAK, and 3XFlag-S910D-FAK adenoviruses
were constructed by subcloning pShuttle-CMV vector using SnaBI and XbaI.

CHAPTER THREE
SPECIFIC AIMS
Adaptive ventricular remodeling is an important mechanism by which
cardiomyocytes respond to biomechanical and neurohumoral stimuli, and change
their shape and function.

Myocytes increase their size by enhanced protein

synthesis, and increased assembly of newly synthesized contractile proteins into
new and existing sarcomeres. The plasma membrane and its associated
cytoskeletal elements are directly involved in sarcomere assembly and FA
provide sites for new sarcomere addition during cardiomyocyte hypertrophy. The
FA complex is highly regulated by FAK, a nonreceptor protein tyrosine kinase
localized to FA. FAK signaling is also essential for both costamerogenesis and
myofibrillogenesis in differentiated skeletal muscle cells in vitro. Mechanical and
neurohumoral stimulation leads to FAK serine and tyrosine phosphorylation at
different residues. FAK phosphorylation produces docking sites for several
classes of signaling molecules, and may be important for the conformationinduced binding of proteins to other structural motifs within the N- and C-terminal
non-catalytic domains of FAK. The role of serine phosphorylation in the
regulation of FAK function during neurohumoral and mechanical stimulation is
still poorly understood. My overall hypothesis is that neurohumoral factors
and mechanical deformation induce FAK serine phosphorylation, which is
important in regulating focal adhesion structure and sarcomerogenesis.
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1: Specific Aim #1: To determine if FAK undergoes serine
phosphorylation in response to neurohumoral and mechanical
stimulation.
In initial experiments, I will subject NRVM to hypertrophic agonists (ET,
PE,

AngII

and

IGF)

and

determine

whether

FAK

undergoes

serine

phosphorylation at S910, S722, S732 and S843, using Western blotting with
phosphospecific antibodies. A similar approach will examine FAK serine
phosphorylation in NRVM subjected to static strain.

2: Specific Aim #2: To determine which serine protein
kinase(s)

are

responsible

for

regulating

FAK

serine

phosphorylation by neurohumoral and mechanical stimuli.
Previous studies from our lab and others indicate that several
serine/threonine protein kinases are located in FA complexes in cardiomyocytes,
including PKC(s) and ERKs. Serine/threonine kinases may be activated by
hypertrophic stimuli and phosphorylate serine residues on FAK. Therefore, I will
stimulate NRVM with phorbol myristate acetate (PMA), a potent pharmacological
activator of novel and classical PKCs, and determine whether FAK undergoes
serine phosphorylation. Second I will use PKC kinase inhibitors, and overexpress
different dominant-negative PKC isoforms, and determine which PKC isoform
causes FAK serine phosphorylation under basal conditions, in response to
neurohumoral stimulation.
The FAK-S910 motif (IESPPP) conforms to the minimal MAPK consensus
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site: a serine directly followed by a proline. However this site differs from typical
PKC consensus sites. Therefore, I will also use different MAPK inhibitors to
determine which MAPK(s) are involved in FAK-S910 phosphorylation. The
MAPKs are not only activated by PKCs, but also other kinases such as Src, PKA,
PI3K, Pyk2 and FAK itself. Third, I will use different inhibitors to determine what
additional pathways might also be involved in FAK-S910 phosphorylation.

3: Specific Aim #3: To determine whether FAK serine
phosphorylation

regulates

FA

complex

structure

and

sarcomerogenesis.
Previous studies indicate that FAK serine phosphorylation controls
fibroblast shape and proliferation.

The morphological effects of FAK serine

phosphorylation in cardiomyocytes are not known, but may serve to regulate FA
complex

assembly/disassembly

and

new

sarcomere

formation

in

cardiomyocytes. First I will generate adenoviruses expressing wildtype and
mutant forms of FAK (wt-FLAG-FAK and S910A-FLAG-FAK). Second, I will
overexpress different forms of FAK, and use co-immunoprecipitation to measure
protein-protein interaction within the FAs. Third, I will overexpress wildtype and
S910A-FAK, and use immunostaining to analyze sarcomere structure. Fourth, I
will use adenoviruses co-expressing YFP-α-actinin or GFP-paxillin with wildtype
and mutant FAK, and stimulate cells with neurohumoral factors. I will then use
TIRF and FRAP to analyze costamere stability in real-time. Fifth, I will use
surface area measurements to determine whether FAK-S910 phosphorylation is
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important for the induction of NRVM spreading. These studies should help to
clarify the role of FAK serine phosphorylation in cardiomyocytes hypertrophy.

CHAPTER FOUR
RESULTS
1.

Hypertrophic

stimulation

induces

FAK

serine

phosphorylation in NRVM.
In my initial experiments, I examined the phosphorylation of FAK tyrosine
and serine residues in NRVM maintained under basal, serum-free conditions,
and in cells treated with hypertrophic agonists. Stimulation of cells with AngII
(30 µM), IGF-1 (50ng/ml), ET-1 (100nM) and PE (10 µM) all increased FAK Y397
and S910 phosphorylation over time (5-30 min), with ET-1 being the most potent
(Figure 7). Stimulation of cells with AngII, ET-1 and PE (but not IGF-1) also
induced FAK Y925 phosphorylation (Figure 7).
Next, I examined whether mechanical stimulation could also induce FAK
serine phosphorylation. NRVM were plated onto collagen-coated Bioflex® culture
dishes and stimulated with 20% static stretch for various time periods. FAK-S910
phosphorylation

was

detectable

under

basal

conditions,

and

S910

phosphorylation increased over time (15-30 min) (Figure 8). In contrast, S722
was constitutively phosphorylated, and there was no effect of 20% static stretch
on its phosphorylation (Figure 8). As ET-1 appeared to be the most potent
agonist for FAK serine phosphorylation, I focused on the signaling pathways and
downstream effects of this hypertrophic stimulus in the majority of subsequent
57
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experiments.
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Figure 7: Different hypertrophic factors induced FAK serine
phosphorylation. NRVM were serum-starved for 18h and subsequently
stimulated with AngII (30µM), IGF (50ng/ml), ET-1 (100nM) and PE (10µM) for
various time periods (5-30 min). NRVM were then washed twice with ice-cold
PBS, scraped from the dishes, and sonicated in lysis buffer. Following
centrifugation, equal amounts of extracted cellular protein (50µg) were separated
by SDS-PAGE followed by immunoblotting with antibodies specific for FAK
phosphorylated

at

Y397,

S910,

Y925.

An

antibody

that

recognizes

phosphorylated and unphosphorylated FAK was also used to ensure equal
loading of the Western blots, and to compare the relative phosphorylation of FAK
at these residues over time.
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Figure 8: The time-course of 20% static stretch induced FAK-S910
and S722 phosphorylation.

NRVM were serum-starved for 18h and

subsequently stimulated with 20% static stretch for various time periods (0-30
min). NRVM were then washed twice with ice-cold PBS and sonicated in lysis
buffer. Equal amounts of extracted cellular protein (50µg) were separated by
SDS-PAGE and immunoblotting. The blot was probed with anti-FAK-S722, antiFAK-S910 and anti-FAK antibody.
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2. ET-1 induced FAK serine phosphorylation in NRVM.
To further analyze the effects of ET-1 on FAK serine phosphorylation, I
used SDS-PAGE and Western blotting to characterize the time-course and doseresponse of ET-1 stimulation on FAK serine phosphorylation at S910, and at
other sites. FAK serine phosphorylation was detectable under basal conditions at
all four residues examined (S722, S732, S843, and S910; Figure 9). Upon ET-1
stimulation, FAK-S910 phosphorylation was detected after 5 min, reached a
maximum within 30 min, and remained relatively constant for up to 120 min. The
maximal FAK-S910 phosphorylation induced by ET-1 was 12.2 ± 1.8 fold, as
compared with unstimulated cells (Figure 9 and Figure 10). I also examined
whether ET-1 regulated FAK phosphorylation at S722, S732 and S843 by
Western blotting using other, commercially available site-specific antibodies. As
shown in Figure 9, the S722 site was highly phosphorylated, but the S732 and
S843 sites were only slightly phosphorylated under basal conditions. After ET-1
stimulation, S722, S732 and S843 phosphorylations were only moderately
increased (Figure 9).
ET-1 induced FAK-S910 phosphorylation increased in a concentrationdependent manner; with a maximal effect achieved at 100 nM (Figure 11). FAKS910 phosphorylation was similar to that of FAK-Y925 phosphorylation, but
occurred later than the autophosphorylation observed at Y397 (Figure 12).
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Figure 9: The time-course of ET-1 induced FAK S722, S732, S843 and
S910 phosphorylation. NRVM were serum-starved for 18 h and subsequently
stimulated with 100nM ET-1 for various time points (0-180 min). NRVM were
washed twice with ice-cold PBS and sonicated in lysis buffer. Equal amount
protein (50µg) were separated by SDS-PAGE and followed by immunoblotting.
The blot was probed with anti-FAK-S722, anti-FAK-S732, anti-FAK-S843, antiFAK-S910 and anti-FAK antibody.
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Figure

10:

The

time-course

of

ET-1

induced

FAK-S910

phosphorylation. Quantification of FAK phosphorylation at S910 was performed
by scanning densitometry and FAK-S910 phosphorylation intensity were
normalized with total FAK intensity. The values were means ± SEM of at least
four independent experiments and were plotted relative to 0 min (i.e., without ET1 stimulation). Asterisks indicate significant differences of values compared with
0 min (P < 0.05, Dunnet’ Test).
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Figure

11:

The

dose

response

of

ET-1

induced

FAK-S910

phosphorylation. NRVM were serum-starved for 18 h and subsequently
stimulated with ET-1 (30 min) with various concentrations (50-200nM). NRVM
were washed twice with ice-cold PBS and sonicated in lysis buffer. Equal amount
protein (50µg) were separated by SDS-PAGE and followed by immunoblotting.
The blot was probed with anti-FAK-S910 and anti-FAK antibody. Values shown
as bars are the mean ± SEM of at least four independent experiments and are
expressed as the fold increases of phosphorylation above control values.
Asterisks indicate significant differences of values compared with control (P <
0.01, Dunnett's Test).
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Figure 12: The time-course of ET-1 induced FAK Y397, Y925 and
S910 phosphorylation. NRVM were serum-starved for 18h and subsequently
stimulated with 100nM ET-1 for various time periods (0-180 min). NRVM were
washed twice with ice-cold PBS and sonicated in lysis buffer. Equal amounts of
extracted cellular protein (50µg) were separated by SDS-PAGE followed by
immunoblotting. The blot was probed with anti-FAK-Y397, anti-FAK-Y925, antiFAK-S910 and anti-FAK antibodies.

3.

FAK

serine

phosphorylation

in

nonfailing
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LV

myocardiumand in dilated cardiomyopathy (DCM).
Next, I examined the phosphorylation status of FAK serine residues in
nonfailing human LV tissue, and in LV tissue from patients undergoing cardiac
transplantation for DCM. As seen in Figure 13, there was no significant difference
in the amount of total FAK relative to total protein in tissue homogenates of both
groups. FAK was serine-phosphorylated in nonfailing LV at all four residues
examined

(S722,

phosphorylation

S732,

was

S843,

reduced

and
by

S910).
~63%

Interestingly,

(P=0.175),

and

FAK-S843
FAK-S910

phosphorylation was reduced ~91% (P<0.05) in DCM as compared to nonfailing,
control hearts.
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Figure 13. FAK serine phosphorylation in nonfailing LV myocardium
and in dilated cardiomyopathy. Human LV tissue extracts (75µg total protein)
from nonfailing (n=11) and DCM (n=6) hearts were separated by SDS-PAGE
followed by Western blotting with phosphospecific and total anti-FAK antibodies,
as indicated. Representative Western blots (left) and quantitative analysis of FAK
serine phosphorylation at each site (right) are depicted. Values shown as bars
are the means ± SEM of relative FAK serine phosphorylation levels at each site.
Asterisks indicate significant differences of values compared with nonfailing (P <
0.05, t-test).
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4. ET-1 induced FAK-S910 phosphorylation is through the
ETAR.
Both ETAR and ETBR are expressed in NRVM, and Clerk et al. have
shown that ETAR stimulation is responsible for the hypertrophic effects of ET1.(Clerk et al., 1994) To check that the ETAR was also responsible for FAK-S910
phosphorylation, cells were pre-treated (0.2-5.0 µM, 90 min) with BQ610 and
PD142893, which are ETA-selective and nonselective ET receptor antagonists,
respectively. When cells were pre-treated with BQ610 (1 and 5µM), the
antagonist significantly reduced basal FAK-S910 phosphorylation by ~60%
(P<0.001) (Figure 14). The nonselective ET receptor antagonist, PD142893 (1
and 5 µM) also reduced basal FAK-S910 phosphorylation by ~70% (P<0.001).
Furthermore, at equimolar concentrations, both antagonists blocked ET-1
induced FAK-S910 phosphorylation (Figure 14), suggesting that the ETAR was
responsible for both basal and ET-1 induced FAK-S910 phosphorylation, as well
as NRVM hypertrophy.
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Figure 14: ET-1 induced FAK-S910 phosphorylation is through the
ETAR. NRVM were pre-treated (1h) with the ETAR-specific antagonist, BQ-610
(0.2-5µM), or the non-selective ETA+BR antagonist, PD142893 (0.2-5µM), and
then stimulated with ET-1 (100nM, 30min). Lysates (50 µg total protein) were
separated by SDS-PAGE followed by Western blotting with anti-FAK-S910 and
anti-FAK antibodies. Top, representative blots are depicted. Bottom, quantitative
analysis of at least four independent Western blotting experiments is depicted.
Data are the means ± SEM, and are expressed as the percentage of ET-1
stimulation in the absence of antagonists. *P<0.05 vs. ET-1 stimulated, control
cells, by 1-way ANOVA followed by Dunnet’s test.
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5. PKC activation is necessary and sufficient for ET-1 induced FAKS910 phosphorylation.
The ETAR is coupled to Gαq, which in turn activates phospholipase C-ß,
generates IP3, and increases the concentration of DAG in the sarolemmal
membrane. DAG, in turn, is required for the activation of classical and novel PKC
isoenzymes in cardiomyocytes.(Endoh et al., 1998; Eskildsen-Helmond et al.,
1997)

NRVM express both classical and novel PKC isoenzymes, including

PKCα, PKCδ and PKCε.(Clerk et al., 1994; Mochly-Rosen et al., 1990) Therefore,
to examine if PKC activation was sufficient to induce FAK-S910 phosphorylation
in response to ET-1, NRVM were treated (5-60min; 2-200nM) with phorbol
myristate acetate (PMA), a highly potent activator of both classical and novel
PKCs. PMA induced a time- (Figure 15) and dose-dependent (Figure 16)
increase in FAK-S910 phosphorylation, which was similar to the effects of ET-1
stimulation, indicating that one or more PKC isoenzymes was sufficient.
PKC inhibitors were then used to determine if ET-1 induced PKC
activation was necessary for FAK-S910 phosphorylation. As seen in Figure 17,
the nonselective PKC inhibitor GF102903X (GFX; 10µM; 1h pre-treatment)
significantly reduced by 60% but did not eliminate FAK-S910 phosphorylation. In
contrast, the classical PKC inhibitor Gö6983 (Gö; 10µM, 1h pre-treatment) was
ineffective, suggesting that a Ca2+-independent, rather than a Ca2+-dependent,
phorbol-ester sensitive PKC was required. In support of this observation, the
PKCδ-selective inhibitor rottlerin (Rot; 10-20µM, 1h pre-treatment) also reduced
FAK-S910 phosphorylation (57%) to approximately the same extent as GFX.

71
None of the small-molecule inhibitors alone increased FAK-S910 phosphorylation.
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Figure

15:

The

time-course

of

PMA-induced

FAK-S910

phosphorylation. NRVM were serum starved for 18 h and subsequently
stimulated with 200nM PMA for various time points (0-60 min). NRVM were
washed twice with ice-cold PBS and sonicated in lysis buffer. Equal amount
protein (50µg) were separated by SDS-PAGE and followed by immunoblotting.
The blot was probed with anti-FAK-S910 and anti-FAK antibody. Data are the
means±SEM of at least four independent experiments. *P<0.05 vs. unstimulated
cells by 1-way ANOVA followed by Dunnet’s test.
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Figure

16:

The

dose-response

of

PMA-induced

FAK-S910

phosphorylation. NRVM were serum starved for 18h and subsequently
stimulated (30 min) with increasing concentrations (0-200 nM) of PMA . NRVM
were washed twice with ice-cold PBS and sonicated in lysis buffer. Equal amount
protein (50µg) were separated by SDS-PAGE and followed by immunoblotting.
The blot was probed with anti-FAK-S910 and anti-FAK antibody. Data are the
means±SEM of at least four independent experiments. *P<0.05 vs. unstimulated
cells by 1-way ANOVA followed by Dunnet’s test.
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Figure 17: ET-1 induced FAK-S910 phosphorylation is through the
novel PKCs. NRVM were pre-treated (1h) with the nonselective PKC inhibitor
GF102903X (GFX; 10µM), the classical PKC inhibitor Gö6983 (Gö; 10µM) or the
PKCδ-selective inhibitor rottlerin (Rot; 10-20µM), and then stimulated with ET-1
(100nM; 30 min). Lysates (50 µg total protein) were separated by SDS-PAGE
followed by Western blotting with anti-FAK-S910 and anti-FAK antibodies. Top,
representative blots are depicted. Bottom, quantitative analysis of at least four
independent Western blotting experiments is depicted. Data are the means±SEM,
and are expressed as the percentage of ET-1 stimulation in the absence of
antagonists. *P<0.05 vs. ET-1 stimulated, control cells, by 1-way ANOVA
followed by Dunnet’s test.
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6. PKC activation is necessary for stretch-induced FAK-S910
phosphorylation.
The small-molecule PKC inhibitors studies described above suggested
that PKCδ was the PKC isoenzyme involved in ET-1 induced FAK-S910
phosphorylation. PKC inhibitors were then used to determine if PKC activation
was also necessary for stretch-induced FAK-S910 phosphorylation. As seen in
Figure 18, the nonselective PKC inhibitor GF102903X (GFX; 10µM; 1h pretreatment) significantly reduced but did not eliminate stretch-induced FAK-S910
phosphorylation. In contrast, the classical PKC inhibitor Gö6983 (Gö; 10µM, 1h
pre-treatment) was ineffective, suggesting that a Ca2+-independent, rather than a
Ca2+-dependent, phorbol-ester sensitive PKC was required. The nonselective
PKC inhibitor GF102903X also blocked basal S722 phosphorylation, but not the
classical PKC inhibitor Gö6983. Thus, these inhibitor studies indicated that a
novel PKC was also involved in stretch-induced FAK-S910 phosphorylation, and
that a novel PKC may also regulate FAK-S722 phosphorylation in NRVM.
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Figure 18: Stretch induced FAK-S910 phosphorylation is through the
novel PKCs. NRVM were pre-treated (1h) with the nonselective PKC inhibitor
GF102903X (GFX; 10µM) or the classical PKC inhibitor Gö6983 (Gö; 10µM) and
then stimulated with 20% static stretch (0-30 min). NRVM were washed twice
with ice-cold PBS and sonicated in lysis buffer. Lysates (50 µg total protein) were
separated by SDS-PAGE followed by Western blotting with anti-FAK-S722, antiFAK-S910 and anti-FAK antibodies.
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7. PKCδ is the PKC isoenzyme involved in ET-1 induced FAKS910 phosphorylation.
As further evidence for a requirement for PKCδ, I examined the tyrosine
and serine phosphorylation of PKCδ by ET-1. Both PKCδ-Y311 and PKCδ-T505
were minimally phosphorylated under basal conditions, but ET-1 markedly
stimulated phosphorylation at both sites (Figure 19). PKCδ-T505 phosphorylation
could also be stimulated by PE, AngII and IGF-1 (Figure 20). In contrast, PKCδS643 was constitutively phosphorylated at this site. To confirm that the ETAR was
responsible for PKCδ activation, cells were pre-treated (0.2-5.0 µM, 90 min) with
BQ610 and PD142893. Both antagonists blocked ET-1 induced PKCδ-T505
phosphorylation (Figure 21), suggesting that the ETAR was responsible for
regulating the phosphorylation of PKCδ-T505. These results also indicate that
PKCδ was indeed activated in response to the agonist.
To further support the PKC inhibitor studies, adenoviral-mediated
overexpression of dnPKCα, dnPKCε and dnPKCδ (100moi, 48hr) were used in
an attempt to block ET-1 induced FAK-S910 phosphorylation. As seen in Figure
22, both dnPKCα (reduced 44%) and dnPKCδ (reduced 55%), but not dnPKCε
demonstrated inhibitory activity. The inhibitory effect of dnPKCα was somewhat
surprising, as the classical PKC inhibitor Gö was ineffective (Figure 17). However,
dnPKCα may not be entirely specific for PKCα inhibition (Whelan and Parker,
1998; Garcia-Paramio et al., 1998), perhaps by interfering with the activation of
other PKC isoenzymes.
However, I found that adenoviral-mediated overexpression of caPKCδ
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was sufficient to induce FAK-S910 (and FAK-Y925) phosphorylation in NRVM in
a time-dependent manner (Figure 23), as compared to cells expressing ß-gal. In
contrast, overexpression of caPKCδ did not affect FAK-Y397 phosphorylation.
These results are consistent with previous studies form our laboratory, indicating
that FAK-Y397 phosphorylation is predominantly regulated by PKCε in
NRVM.(Heidkamp et al., 2003) Furthermore, when I infected cells with different
doses of Adv-caPKCδ, FAK-S910 phosphorylation increased in a dosedependent manner (Figure 24). Overall, these results provide strong evidence
that PKCδ is the responsible PKC isoenzyme.
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Figure 19: PKCδ is activated in response to ET-1. NRVM were serumstarved for 18h and subsequently stimulated with ET-1 (100 nM) for various time
periods (0-30 min). NRVM were washed twice with ice-cold PBS and sonicated in
lysis buffer. Lysates (50 µg total protein) were separated by SDS-PAGE followed
by Western blotting with anti-PKCδ-Y311, anti-PKCδ-T505, anti-PKCδ-S643, and
anti-PKCδ antibodies.
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Figure 20: PKCδ is activated in response to different hypertrophic
factors. NRVM were serum-starved for 18h and subsequently stimulated with
AngII (30µM), IGF (50ng/ml), ET-1 (100nM) and PE (10µM) for various time
points (0-30 min). NRVM were washed twice with ice-cold PBS and sonicated in
lysis buffer. Lysates (50 µg total protein) were separated by SDS-PAGE followed
by Western blotting with anti-PKCδ-T505 and anti-PKCδ antibodies.
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Figure 21: ET-1 induced PKCδ
δ T505 phosphorylation is through the
ETAR. NRVM were pre-treated (1h) with the ETAR-specific antagonist, BQ-610
(0.2-5µM), or the non-selective ETA+BR antagonist, PD142893 (0.2-5µM), and
then stimulated with ET-1 (100nM, 30min). NRVM were washed twice with icecold PBS and sonicated in lysis buffer.

Lysates (50 µg total protein) were

separated by SDS-PAGE followed by Western blotting with anti-PKCδ-T505 and
anti-PKCδ

antibodies.

Top,

representative

blots

are

depicted.

Bottom,

quantitative analysis of at least four independent Western blotting experiments is
depicted. Data are the means±SEM, and are expressed as the percentage of ET1 stimulation in the absence of antagonists. *P<0.05 vs. ET-1 stimulated, control
cells, by 1-way ANOVA followed by Dunnet’s test.
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Figure 22: PKCδ is the PKC isoenzyme involved in FAK-S910
phosphorylation. NRVM were infected with Adv-β-gal, Adv-dnPKCα, AdvdnPKCε and Adv-dnPKCδ (100moi, 48h) and then stimulated with ET-1 (100nM,
30min). NRVM were washed twice with ice-cold PBS and sonicated in lysis buffer.
Lysates (50 µg total protein) were separated by SDS-PAGE followed by Western
blotting with anti-FAK-S910 and anti-PKCδ antibodies. Top, representative blots
are depicted. Bottom, quantitative analysis of at least four independent Western
blotting experiments is depicted. Quantification of FAK phosphorylation at S910
was performed by scanning densitometry and FAK-S910 phosphorylation
intensity were normalized with total FAK intensity. The values were means ±
SEM of at least four independent experiments and were plotted relative Adv-βgal. Asterisks indicate significant differences of values compared with Adv-β-gal
plus ET-1 stimulation (P < 0.05, Dunnet’s test).
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Figure 23: The time-course of Adv-caPKCδ induced FAK-S910
phosphorylation. NRVM were infected with Adv-β-gal (50moi), and AdvcaPKCδ (50moi) for various time-points. NRVM were washed twice with ice-cold
PBS and sonicated in lysis buffer. Lysates (50 µg total protein) were separated
by SDS-PAGE followed by Western blotting with anti-FAK-Y397 anti-FAK-Y925,
anti-FAK-S910 and anti-PKCδ antibodies.
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Figure

24:

caPKCδ

is

sufficient

to

induced

FAK-S910

phosphorylation. NRVM were infected with Adv-β-gal (50moi) or Adv-caPKCδ
(5-50 moi) for 48h. NRVM were washed twice with ice-cold PBS and sonicated in
lysis buffer. Cell extracts (50µg total protein) were separated by SDS-PAGE
followed by Western blotting with anti-FAK-S910, anti-FAK and PKCδ-specific
antibody, as indicated. Quantification of FAK phosphorylation at S910 was
performed by scanning densitometry and FAK-S910 phosphorylation intensity
were normalized with total FAK intensity. The values were means ± SEM of at
least four independent experiments and were plotted relative Adv-β-gal. Asterisks
indicate significant differences of values compared with Adv-β-gal (P < 0.05,
Dunnet’s test).
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8. ET-1 induces both ERK1/2 and FAK-S910 phosphorylation,
which is mediated by Raf-1.
Examination of the sequence surrounding FAK-S910 (ISPPP) using GPS
2.1 software indicated that this site was not an optimal PKC phosphorylation site,
but rather was most consistent with a site phosphorylated by ERK1/2.
Furthermore, Hunger-Glaser et al. demonstrated that stimulation of Swiss 3T3
cells with bombesin, lysophosphatidic acid and epidermal growth factor all
promoted a striking increase in the phosphorylation of FAK-S910 in a PKC- and
ERK1/2-dependent manner.(Hunger-Glaser et al., 2004; Hunger-Glaser et al.,
2003) Therefore, I next examined the time-course of ERK1/2 activation and FAKS910 phosphorylation in response to ET-1 (100nM, 0-60 min). As seen in Figure
25, ERK1/2 phosphorylation increased ~6-fold within 5 min of ET-1 stimulation.
ERK1/2 activation preceded the peak of FAK-S910 phosphorylation, which
occurred at 30-90 min (Figures 3 and 4). ET-1 induced ERK1/2 activation was
partially dependent on PKCδ, as overexpression of dnPKCδ blocked ER1/2
phosphorylation (reduced 86%) over the same time period (Figure 26). I also
found that adenoviral-mediated overexpression of caPKCδ was sufficient to
induce ERK1/2 phosphorylation in NRVM in a dose- (Figure 27) and timedependent manner (Figure 28), as compared to Adv-ß-gal.
ET-1 induced ERK1/2 and FAK-S910 phosphorylation were also blocked
by two different inhibitors of MEK1/2 (i.e., PD98059 and U0126), the upstream
regulators of ERK1/2 (Figure 29). In contrast, SB203580, a highly specific
inhibitor p38MAPK was without effect. The involvement of Raf-1, an upstream
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regulator of the ERK cascade in cardiomoyocytes (Zou et al., 1996) was
examined by pharmacological inhibition with sorafenib; (1-10µM, 1h pretreatment) or overexpression of dnRaf-1.(Iijima et al., 2002) As seen in Figures
30 and 31, both approaches reduced ERK1/2 and FAK-S910 phosphorylation in
response to ET-1 stimulation. Overall, these results indicate that ET-1 induced
FAK-S910

phosphorylation

in

NRVM

1→MEK1/2→ERK1/2 signaling pathway.

involves

a

PKCδ→Raf-
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Figure 25: The time-course of ET-1 induced ERK1/2 phosphorylation.
NRVM were serum-starved for 18 h and subsequently stimulated with 100nM ET1 for various time periods (0-60 min). NRVM were washed twice with ice-cold
PBS and sonicated in lysis buffer. Equal amounts of extracted cellular protein
(50µg) were separated by SDS-PAGE and followed by immunoblotting. The blot
was probed with anti-phospho-ERK1/2 and anti-ERK2 antibodies. Quantification
of ERK1/2 phosphorylation was performed by scanning densitometry and
ERK1/2 phosphorylation intensity was normalized with ERK2 intensity.

The

values were means ± SEM of at least four independent experiments and were
plotted relative to 0 min (i.e., without ET-1 stimulation). Asterisks indicate
significant differences of values compared with 0 min (P < 0.05, Dunnet’s test).
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Figure 26: ET-1 induced ERK1/2 phosphorylation was through PKCδ.
NRVM were infected with Adv-β-gal or Adv-dnPKCδ (100moi, 48h) and then
stimulated with ET-1 (100nM, 10min). NRVM were washed twice with ice-cold
PBS and sonicated in lysis buffer. Lysates (50 µg total protein) were separated
by SDS-PAGE followed by Western blotting with anti-phopho-ERK1/2, anti-ERK2,
anti-PKCδ and anti-GAPDH antibodies. Top, representative blots are depicted.
Bottom, quantitative analysis of at least four independent Western blotting
experiments is depicted. Quantification of FAK phosphorylation at S910 was
performed by scanning densitometry and FAK-S910 phosphorylation intensity
were normalized with total FAK intensity. The values were means ± SEM of at
least four independent experiments and were plotted relative Adv-β-gal plus ET-1
stimulation. Asterisks indicate significant differences in values compared with
Adv-β-gal plus ET-1 stimulation (P < 0.05, Dunnet’s test).
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Figure 27: caPKCδ is sufficient to induced ERK1/2 phosphorylation.
NRVM were infected with Adv-β-gal (50moi) or Adv-caPKCδ (5-50 moi) for 48h.
NRVM were washed twice with ice-cold PBS and sonicated in lysis buffer. Cell
extracts (50µg total protein) were separated by SDS-PAGE followed by Western
blotting with FAK-S910 and anti-FAK antibodies, and PKCδ-specific antibody, as
indicated.
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Figure 28: The time-course of Adv-caPKCδ induced ERK1/2
phosphorylation. NRVM were infected with Adv-β-gal (10moi), or Adv-caPKCδ
(10moi) for various time-periods (0-48hr). NRVM were washed twice with ice-cold
PBS and sonicated in lysis buffer. Lysates (50 µg total protein) were separated
by SDS-PAGE followed by Western blotting with anti-phospho-ERK1/2, antiERK2 and anti-PKCδ antibodies.
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Figure 29: ET-1 induced FAK-S910 phosphorylation is through
MEK1/2-ERK1/2. NRVM were pre-treated (1h) with the p38MAPK inhibitor
SB203580 (10µM), the MEK1/2 inhibitor PD98059 (30µM) or the MEK1/2
inhibitor U0126 (1-10µM); and then stimulated with ET-1 (100nM, 30min). NRVM
were washed twice with ice-cold PBS and sonicated in lysis buffer. Lysates (50
µg total protein) were separated by SDS-PAGE followed by Western blotting with
anti-FAK-S910, anti-FAK antibodies, anti-phospho-ERK1/2 and anti-ERK2. Top,
representative blots are depicted. Bottom, quantitative analysis of at least four
independent Western blotting experiments is depicted. Data are the means±SEM,
and are expressed as the percentage of ET-1 stimulation in the absence of
antagonists. *P<0.05 vs. ET-1 stimulated, control cells, by 1-way ANOVA
followed by Dunnet’s test.
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Figure 30: The Raf-1 inhibitor sorafenib blocked ET-1 induced FAKS910 phosphorylation. NRVM were pre-treated (1h) with the Raf-1 inhibitor
Sorafenib (0-10µM) and then stimulated with ET-1 (100nM, 30min). NRVM were
washed twice with ice-cold PBS and sonicated in lysis buffer. Lysates (50 µg total
protein) were separated by SDS-PAGE followed by Western blotting with antiFAK-S910, anti-FAK antibodies, anti-phospho-ERK1/2 and anti-ERK2.
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Figure 31: ET-1 induced FAK-S910 phosphorylation was through Raf1. NRVM were infected with Adv-β-gal or Adv-dnRaf-1 (50moi, 48h) and then
stimulated with ET-1 (100nM, 10min). NRVM were washed twice with ice-cold
PBS and sonicated in lysis buffer. Lysates (50 µg total protein) were separated
by SDS-PAGE followed by Western blotting with Western blotting with anti-FAKS910, anti-FAK antibodies, anti-phospho-ERK1/2, anti-ERK2 and anti-Raf-1
antibodies.
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9 Stretch-induced FAK-S910 phosphorylation is through the
MEK1/2-ERK1/2 pathway.
Yazaki et al. have shown that MAPKs can be activated by mechanical
stretch.(Yazaki and Komuro, 1992) Therefore, we next examined the time-course
of ERK1/2 activation in response to static stretch (20%, 0-30 min). ERK1/2
phosphorylation increased within 15 min of 20% static stretch (Figure 32), which
preceded the peak of FAK-S910 phosphorylation. Stretch-induced ERK1/2 and
FAK-S910 phosphorylations were also blocked by the MEK1/2 inhibitor U0126,
the upstream regulators of ERK1/2 (Figure 32). Overall, these results show that,
like ET-1 induced FAK-S910, stretch-induced FAK-S910 phosphorylation in
NRVM via an nPKC→ MEK1/2→ERK1/2 signaling pathway.
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Figure 32: PKC and MEK1/2-ERK1/2 are involved in stretch-induced
FAK-S910 phosphorylation. NRVM were pre-treated (1h) with the nonselective
PKC inhibitor GF102903X (GFX; 10µM) or the MEK1/2 inhibitor U0126 (10µM)
and then stimulated with 20% static stretch (0-30 min). NRVM were washed
twice with ice-cold PBS and sonicated in lysis buffer. Lysates (50 µg total protein)
were separated by SDS-PAGE followed by Western blotting with anti-FAK-S722,
anti-FAK-S910 anti-phospho-ERK1/2 and anti-GAPDH antibodies.
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10. ERK1/2 phosphorylation in nonfailing LV myocardium and
in dilated cardiomyopathy.
I also examined the phosphorylation status of ERK1/2 in nonfailing human
LV tissue, and in LV tissue from patients undergoing cardiac transplantation for
DCM. As seen in Figure 33, there was no significant difference in the amounts of
either active ERK1/2 or total ERK2 in tissue homogenates of either group.
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Figure 33. ERK1/2 phosphorylation in nonfailing LV myocardium and
in dilated cardiomyopathy. Human LV tissue extracts (75µg total protein) from
nonfailing (GOH; n=12) and DCM (n=12) hearts were separated by SDS-PAGE
followed by Western blotting with phosphospecific ERK1/2 and total anti-ERK2
antibodies, as indicated. Representative Western blots (left) and quantitative
analysis of ERK1/2 phosphorylation at each site (right) are depicted. Values
shown as bars are the mean ± SEM of at least four independent experiments and
are expressed as the fold increases of phosphorylation above control values.
Asterisks indicate significant differences of values compared with nonfalling (P <
0.05, t-test).
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11 Src and Fyn are also involved in ET-1 induced FAKS910 phosphorylation.
When NRVM were treated with GF102903X (Figure 17), rottlerin (Figure
17) or dnPKCδ (Figure 22), ET-1 induced FAK-S910 phosphorylation was only
reduced by approximately 50%, suggesting that other signaling pathways might
also be involved. ET-1 also stimulates SFKs, and SFKs are important for ET-1
induced cardiomyocyte hypertrophy.(Kovacic et al., 1998) Therefore, to
investigate whether SFKs were involved in FAK-S910 phosphorylation, the SFKspecific inhibitor PP2, along with its inactive analog PP3, were used. NRVM were
pre-treated (1h) with PP2 (5-25µM) or PP3 (25 µM) and then stimulated with ET1 (100nM, 30 min). ET-1 induced FAK-S910 phosphorylation was dosedependently reduced by PP2, but not PP3 (Figure 34). To further support the
SFK inhibitor studies, I used adenoviral-mediated overexpression of dnSrc (1050 moi) or dnFyn (10-50 moi). As seen in Figure 35 and 36, both dnSrc and
dnFyn significantly reduced ET-1 induced FAK-S910 phosphorylation, suggesting
that Src and/or Fyn were involved.
As further evidence for the involvement of two parallel signaling pathways,
I noted that neither PP2 nor rottlerin alone was sufficient to eliminate FAK-S910
phosphorylation (Figure 37). However, when NRVM were pretreated with both
Rotterlin and PP2 at the same time, the inhibitor combination completely blocked
ET-1 induced FAK-S910 phosphorylation (Figure 37). These results also provide
evidence that Src and Fyn were involved independently of the PKCδ→ Raf1→MEK1/2→ERK1/2 signaling pathway.
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Figure 34: The SFK inhibitor PP2 blocks ET-1 induced FAK-S910
phosphorylation. NRVM were pretreated (1h) with PP2 (5-25µM) or PP3 (25µM)
and then stimulated with ET-1 (100nM, 30min). NRVM were washed twice with
ice-cold PBS and sonicated in lysis buffer. Lysates (50 µg total protein) were
separated by SDS-PAGE followed by Western blotting with anti-FAK-S910, antiFAK antibodies, anti-phospho-ERK1/2 and anti-ERK2. Top, representative blots
are depicted. Bottom, quantitative analysis of at least four independent Western
blotting experiments is depicted. Data are the means±SEM, and are expressed
as the percentage of ET-1 stimulation in the absence of antagonists. *P<0.05 vs.
ET-1 stimulated, control cells, by 1-way ANOVA followed by Dunnet’s test.
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Figure 35: ET-1 induced FAK-S910 phosphorylation is through Src.
NRVM were infected with Adv-β-gal (50moi, 48hr) or Adv-dnSrc (10-50moi, 48h)
and then stimulated with ET-1 (100nM, 30min). NRVM were washed twice with
ice-cold PBS and sonicated in lysis buffer. Lysates (50 µg total protein) were
separated by SDS-PAGE followed by Western blotting with anti-FAK-S910, antiFAK, anti-Src. and anti-GAPDH antibodies. Top, representative blots are
depicted. Bottom, quantitative analysis of at least four independent Western
blotting experiments is depicted. Quantification of FAK phosphorylation at S910
was performed by scanning densitometry and FAK-S910 phosphorylation
intensity were normalized with total FAK intensity. The values were means ±
SEM of at least four independent experiments and were plotted relative Adv-βgal plus ET-1 stimulation. Asterisks indicate significant differences of values
compared with Adv-β-gal plus ET-1 stimulation (P < 0.05, Dunnet’s test).

101

Figure 36: ET-1 induced FAK-S910 phosphorylation is through Fyn.
NRVM were infected with empty virus (50moi, 48hr) or Adv-dnFyn (10-50moi,
48h) and then stimulated with ET-1 (100nM, 10min). NRVM were washed twice
with ice-cold PBS and sonicated in lysis buffer. Lysates (50 µg total protein) were
separated by SDS-PAGE followed by Western blotting with anti-FAK-S910, antiFAK-Y925 and anti-GAPDH.
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Figure 37: Both SFKs and PKCδ
δ are both involved in ET-1 induced
FAK-S910 phsophorylation. NRVM were pretreated (1h) with PP2 (25µM), PP3
(25µM), Rottlerin (Rot; 20µM), Rottlerin+PP2 or Rottlerin+PP3 and then
stimulated with ET-1 (100nM, 30min). Lysates (50 µg total protein) were
separated by SDS-PAGE followed by Western blotting with anti-FAK-S910 and
anti-FAK antibodies. Top, representative blots are depicted. Bottom, quantitative
analysis of at least four independent Western blotting experiments is depicted.
Data are the means±SEM, and are expressed as the percentage of ET-1
stimulation in the absence of antagonists. *P<0.05 vs. ET-1 stimulated cells by 1way ANOVA followed by Dunnet’s test; #P<0.05 vs. ET-1 stimulated cells treated
with Rot+PP2 by 1-way ANOVA followed by Student-Newman-Keuls test.
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12 FAK and PYK2 are not involved in ET-1 induced FAK-S910
phosphorylation.
Previous studies from our laboratory have shown that both FAK and PYK2
can be activated by ET-1.(Bayer et al., 2001; Eble et al., 2000b) When FAK-Y397
or PYK2-Y402 is phosphorylated, either kinase can provide a docking site for Src
and promote subsequent Src activation. Active Src can then phosphorylate
additional tyrosine phosphorylation sites on FAK (Y576 and Y577) or PYK2
(Y579 and Y580), thereby enhancing their kinase activities against exogenous
substrates. The activated FAK/Src and PYK2/Src signaling complexes can also
initiate a cascade of phosphorylation events leading to new protein–protein
interactions, and trigger several signaling pathways that eventually lead to
different cellular responses.(Schlaepfer et al., 1999) For example, when FAKY925 and PYK2-Y881 are phosphorylated, they form a docking site for Grb2,
which then recruits son-of-sevenless (SOS) into the complex and activates the
downstream Ras-Raf-MEK-ERK signaling pathway.(Schlaepfer et al., 1994;
Schlaepfer et al., 1998)
Therefore, I next examined whether FAK or PYK2 was involved in ET-1
induced FAK-S910 phosphorylation. First, cells were pre-treated (1h) with the
highly selective FAK kinase inhibitor PF573228 (1-10µM)(Slack-Davis et al.,
2007), and then stimulated with 100nM ET-1 for 30 min. ET-1 induced FAK-Y397
phosphorylation was dose-dependently reduced by PF573228 (Figure 38). ET-1
induced paxillin-Y118 phosphorylation, a known FAK/Src substrate, was also
reduced by PF573228. In contrast, ET-1 induced ERK1/2 and FAK-S910
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phosphorylations were unaffected by PF573228, indicating that FAK was not a
major upstream regulator of ERK1/2 activation in response to ET-1. To further
support the FAK inhibitor studies, adenoviral-mediated overexpression of GFPFRNK (10moi, 48hr) was used to block ET-1 induced FAK-S910 phosphorylation.
FRNK is the autonomously expressed C-terminal domain of FAK, which, when
overexpressed in NRVM, displaces FAK from focal adhesions and inhibits FAKdependent signal transduction.(Heidkamp et al., 2002) As seen in Figure 39,
overexpression of GFP-FRNK was ineffective, but rottlerin and U0126 were still
capable of attenuating ET-1 induced FAK-S910 phosphorylation. I also found out
that GFP-FRNK was highly phosphorylated at the S217 residue (equivalent to
the S910 residue on FAK) even under basal conditions.
Next, I examined PYK2’s role in ET-1 induced FAK-S910 phosphorylation
by overexpressing two different dominant-negative inhibitors of PYK2-dependent
signaling. CADTK/CAKß-related non-kinase (CRNK) is the C-terminal domain of
PYK2, which is analogous to FRNK, the C-terminal domain of FAK. Our
laboratory has previously demonstrated that CRNK inhibits PYK2 in NRVM. (Hart
et al., 2008) I also used an Adv that expresses a mutant form of PYK2 in which
the Y402 autophosphorylation site was mutated to phenylalanine (Y402F-PYK2).
(Heidkamp et al., 2005)

First, NRVM were infected with Adv-FLAG-CRNK

(10moi) or Y402F-PYK2 (50moi) for 48hr and then stimulated with ET-1 (100nM;
30min). Overexpression of Y402F-PYK2 had no effect (Figure 40), but FLAGCRNK partially blocked ET-1 induced FAK-S910 phosphorylation. To confirm that
CRNK and Y402F-PYK2 were specific for inhibiting PYK2, I overexpressed a
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mixture of 2 shRNAs specific for rat PYK2. The PYK2 shRNA1 and PYK2
shRNA2 mixture (20 moi, 72hr) was thus used to “knock down” PYK2 expression
in NRVM. As seen in Figure 41, PYK2 expression was significantly decreased by
overexpression of PYK2 shRNA1/2. However, down regulation of PYK2 had no
effect on ET-1 induced FAK-S910 phosphorylation or ERK1/2 activation in NRVM.
Taken together, these results indicate that neither FAK nor PYK2 were
necessary for ET-1 induced FAK-S910 phosphorylation.
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Figure 38: FAK is not involved in ET-1 induced FAK-S910
phsophorylation. NRVM were pretreated (1h) with PF573228 (1-10µM) and
then stimulated with ET-1 (100nM, 30min). NRVM were washed twice with icecold PBS and sonicated in lysis buffer. Lysates (50 µg total protein) were
separated by SDS-PAGE followed by Western blotting with anti-FAK-Y397, antiFAK-S910, anti-FAK, anti-phospho-ERK1/2, anti-ERK2 and anti-Y188 paxillin
antibodies.
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Figure 39: ET-1 induced FAK-S910 phosphorylation is not through
FAK. NRVM were infected with adv-GFP virus (10moi, 48hr) or Adv-FRNK
(10moi, 48h). Cells were pretreated (1h) with rottlerin (Rot; 20µM) and U0126 (10
µM) and then stimulated with ET-1 (100nM, 30min). NRVM were washed twice
with ice-cold PBS and sonicated in lysis buffer. Lysates (50 µg total protein) were
separated by SDS-PAGE followed by Western blotting with anti-FAK-S910, antiFAK, and anti-GFP antibodies.
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Figure 40: Pyk2 is not involved in ET-1 induced FAK-S910
phosphorylation. NRVM were infected with adv-β-gal virus (10moi, 48hr), advY402F-PYK2 (50moi, 48hr) or Adv-CRNK (10moi, 48h) and then stimulated with
ET-1 (100nM, 30min). NRVM were washed twice with ice-cold PBS and
sonicated in lysis buffer. Lysates (50 µg total protein) were separated by SDSPAGE followed by Western blotting with anti-FAK-S910, anti-FAK, and anti-FLAG
antibodies.
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Figure 41: ET-1 induced FAK-S910 phosphorylation is not through
PYK2. NRVM were infected with Adv-Luciferase (Luc)-shRNA (40moi, 72hr) or
Adv-PYK2-shRNA-1 and Adv-PYK2-shRNA-2 mixture (20moi for each, 72hr) and
then stimulated with ET-1 (100nM, 30min). NRVM were washed twice with icecold PBS and sonicated in lysis buffer. Lysates (50 µg total protein) were
separated by SDS-PAGE followed by Western blotting with anti-FAK-S910, antiFAK, anti-PYK2 and anti-GAPDH antibodies.
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13. FAK but not PYK2 is involved in stretch-induced FAK-S910
phosphorylation.
FAK can be activated by mechanical stretch, and FAK is also involved in
mechanical stretch induced MAPK activation.(Aikawa et al., 2002; Seko et al.,
1999) FAK inhibitors were then used to determine if static stretch induced ERK
activation was necessary for FAK-S910 phosphorylation. Cells were pre-treated
(1h) with PF573228 (0.1-10µM) and then stimulated with 20% static stretch for 10
or 30 min. PF573228 (10µM) effectively reduced FAK-Y397 phosphorylation, and
the drug also blocked stretch-induced ERK1/2 phosphorylation (Figure 42).
Furthermore, PF573228 blocked stretch-induced FAK-S910 phosphorylation
(Figure 43).
PYK2 has been implicated in linking G protein-coupled receptors to
activation of mitogen-activated protein kinase cascades and cellular growth in a
variety of cell types. To investigate whether PYK2 is also involved in stretchinduced FAK-S910 phosphorylation, NRVM were infected with AdvCRNK to
inhibit PYK2 activation. As seen in Figure 44, CRNK overexpression did not
reduce stretch-induced FAK-S910 phosphorylation, suggesting that PYK2 was
not involved. These results also provide evidence that stretch-induced FAK-S910
phosphorylation is through a FAK→MEK1/2→ERK1/2 signaling pathway, but not
aPYK2 →MEK1/2→ERK1/2 signaling pathway.
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Figure

42:

FAK

is

involved

in

stretch-induced

ERK1/2

phsophorylation. NRVM were pretreated (1h) with PF573228 (0.1-10µM) and
then stimulated with static stretch (20%, 30 min). NRVM were washed twice with
ice-cold PBS and sonicated in lysis buffer. Lysates (50 µg total protein) were
separated by SDS-PAGE followed by Western blotting with anti-Y397, antiphospho-ERK1/2 and anti-GAPDH antibodies.
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Figure

43:

FAK

is

involved

in

stretch-induced

FAK-S910

phsophorylation. NRVM were pretreated (1h) with PF573228 (10µM) and then
stimulated with static stretch (20%, 10 min). NRVM were washed twice with icecold PBS and sonicated in lysis buffer. Lysates (50 µg total protein) were
separated by SDS-PAGE followed by Western blotting with anti-FAK-S910 and
anti-GAPDH antibodies.
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Figure 44: Stretch induced FAK-S910 phosphorylation is not through
the PYK2. NRVM were infected with adv-β-gal virus (50moi, 48hr) or Adv-CRNK
(50moi, 48h) and then stimulated with static stretch (20%, 30min). NRVM were
washed twice with ice-cold PBS and sonicated in lysis buffer. Lysates (50 µg total
protein) were separated by SDS-PAGE followed by Western blotting with antiFAK-S910, anti-FAK, anti-phospho-ERK1/2 and anti-ERK2 antibodies.
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14. ET-1 induced FAK-S910 phosphorylation is not
through epidermal growth factor receptor (EGFR) or plateletderived growth factor receptor (PDGFR) transactivation.
Recently, it has become evident that agonists of GPCRs are potent stimuli
for the activation of the EGFR, although they do not directly bind to the EGFR.
Transactivation of the EGFR by GPCRs is very rapid (detectable within minutes
after GPCR stimulation) and the GPCR-induced release of EGFR ligands cannot
be easily detected. When EGFR is activated, it can form a docking site for Src,
thereby leading to Src activation.(Chung and Walker, 2007; Iwasaki et al., 1999;
Lee et al., 2011) Therefore, I next examined whether EGFR or PDGFR are
involved in ET-1 induced FAK-S910 phosphorylation. The cells were pre-treated
(1h) with AG1478 (0.25-2.5µM) or AG1296 (2.5-25µM), which are specific
inhibitors of EGFR and PDGFR, respectively, and then stimulated with 100nM
ET-1 for 30min. Neither AG1478 nor AG1296 abolished ET-1 induced FAK-S910
phosphorylation (Figure 45). These results indicate that ET-1 induced
transactivation of these receptors was not involved in ET-1 induced FAK-S910
phosphorylation.
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Figure 45: ET-1 induced FAK-S910 phosphorylation is not through
EGFR or PDGFR transactivation. NRVM were pretreated (1h) with with the
EGFR-specific antagonist, AG1478 (0.25-2.5µM) or the PDGFR-specific
antagonist AG1296 (2.5-25 µM ) and then stimulated with ET-1 (100nM, 30min).
NRVM were washed twice with ice-cold PBS and sonicated in lysis buffer.
Lysates (50 µg total protein) were separated by SDS-PAGE followed by Western
blotting with anti-FAK-S910 and anti-GAPDH antibodies.
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15. Reactive oxygen species (ROS) are not involved in
ET-1 induced FAK-S910 phosphorylation.
Several studies have demonstrated that ROS play a role as second
messengers to regulate mitogenic signal transduction in various cell types, such
as smooth muscle cells, endothelial cells, and fibroblasts(Kunsch and Medford,
1999). ET-1 and PE increase ROS levels and ERK activity of adult rat cardiac
myocytes, and the effect can be inhibited by the antioxidant N-acetylcysteine
(NAC).(Tanaka et al., 2001) Therefore, I next examined whether ROS were
involved in ET-1 induced FAK-S910 phosphorylation. The cells were pre-treated
(1h) with NAC (1mM), or 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid
(Trolox®, 20µM), a water-soluble derivative of vitamin E, and then stimulated with
100nM ET-1 for 30min. Neither NAC nor Trolox significantly reduced ET-1
induced FAK-S910 or ERK1/2 phosphorylation (Figure 46). These results
indicate that ROS was not involved in ET-1 induced FAK-S910 phosphorylation.
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Figure 46: Reactive oxygen species (ROS) was not involved in ET-1
induced FAK-S910 phosphorylation. NRVM were pretreated (1h) with with the
antioxidant, Trolox® (20µM) or NAC (1mM) and then stimulated with ET-1
(100nM, 30min). NRVM were washed twice with ice-cold PBS and sonicated in
lysis buffer. Lysates (50 µg total protein) were separated by SDS-PAGE followed
by Western blotting with anti-FAK-S910, anti-FAK and anti-phospho-ERK1/2 and
anti-ERK2 antibodies.

118
16. SFK-dependent FAK-S910 phosphorylation involves
serine protein kinases other than ERK1/2.
SFKs are members of the non-receptor protein tyrosine kinase family,
and are important in RTK-mediated ERK1/2 activation.(Kim et al., 2009; Zou et
al., 1998) However, Yamazaki et al. have suggested that ET-1 induced ERK1/2
phosphorylation

is

not

through

Src-

or

Ras-dependent

pathways

in

cardiomyocytes.(Yamazaki et al., 1999) To examine whether SFKs were involved
in ET-1 induced ERK1/2 activation, NRVM were pre-treated (1h) with PP2 (or its
inactive analog PP3) to inhibit SFKs; or cells were infected with Adv’s that
express dnSrc or dnFyn (50moi, 48h), and then stimulated with 100nM ET-1 for
10min. ET-1 induced ERK1/2 phosphorylation was not reduced by pre-treatment
with PP2 (Figure 47), and was only partially inhibited by overexpression of dnSrc
but not dnFyn (Figure 48 and 49), suggesting that Src and Fyn mediate FAKS910 phosphorylation by the activation of serine protein kinase(s) other than
ERK1/2.
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Figure 47: The SFK inhibitor PP2 does not block ET-1 induced
ERK1/2 phosphorylation. NRVM were pretreated (1h) with PP2 (25µM) or PP3
(25µM) and then stimulated with ET-1 (100nM, 10min). NRVM were washed
twice with ice-cold PBS and sonicated in lysis buffer. Lysates (50 µg total protein)
were separated by SDS-PAGE followed by Western blotting with anti-FAK-S910,
anti-FAK antibodies, anti-phospho-ERK1/2 and anti-ERK2. Top, representative
blots are depicted. Bottom, quantitative analysis of at least four independent
Western blotting experiments is depicted. Data are the means±SEM, and are
expressed as the percentage of ET-1 stimulation in the absence of antagonists.
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Figure 48: Overexpression dnSrc partially blocked ET-1 induced
ERK1/2 phosphorylation. NRVM were infected with empty virus (50moi, 48hr)
or Adv-dnSrc (10-50moi, 48h) and then stimulated with ET-1 (100nM, 10min).
Lysates (50 µg total protein) were separated by SDS-PAGE followed by Western
blotting with anti-phospho-ERK1/2 and anti-ERK2 antibodies. Top, representative
blots are depicted. Bottom, quantitative analysis of at least four independent
Western

blotting

experiments

is

depicted.

Quantification

of

ERK1/2

phosphorylation was performed by scanning densitometry and ERK1/2
phosphorylation intensity were normalized with total FAK intensity. The values
were means ± SEM of at least four independent experiments and were plotted
relative empty virus plus ET-1 stimulation. Asterisks indicate significant
differences of values compared with empty virus empty virus plus ET-1
stimulation (P < 0.05, Dunnet).
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Figure

49:

Fyn

is

not

involved

in

ET-1

induced

ERK1/2

phosphorylation. NRVM were infected with empty virus (50moi, 48hr) or AdvdnFyn (10-50moi, 48h) and then stimulated with ET-1 (100nM, 10min). NRVM
were washed twice with ice-cold PBS and sonicated in lysis buffer. Lysates (50
µg total protein) were separated by SDS-PAGE followed by Western blotting with
anti-phospho-ERK1/2 and anti-ERK2 antibodies.
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17. ET-1 induced FAK-S910 phosphorylation is also through
MEK5/ERK5.
Villa-Moruzzi (2007) demonstrated that stimulation of Swiss 3T3 cells with
PMA induced FAK-S910 phosphorylation via activation of ERK5.(Villa-Moruzzi,
2007) Therefore, I next examined the time course of ERK5 activation in response
to ET-1 (100nM, 0-60 min), and compared it to the time-course of FAK-S910
phosphorylation.

As seen in Figure 50, ERK5 phosphorylation increased

significantly within 5 min of ET-1 stimulation. ERK5 activation preceded the peak
of FAK-S910 phosphorylation, which occurred at 30-90 min (Figure 50). To
further examine whether ERK5 was involved, I used adenoviral-mediated
overexpression of dnERK5 (10-50 moi), which dose-dependently reduced FAKS910

phosphorylation

(Figure

51).

Conversely,

adenoviral-mediated

overexpression of caMEK5 (the upstream activator of ERK5) was sufficient to
induced FAK-S910 phosphorylation (Figure 52). These results indicate that
ERK5 is in part responsible for ET-1 induced FAK-S910 phosphorylation.
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Figure 50: The time-course of ET-1 induced ERK15 phosphorylation.
NRVM were serum starved for 18 h and subsequently stimulated with 100nM ET1 for various time periods (0-60 min). NRVM were washed twice with ice-cold
PBS and sonicated in lysis buffer. Equal amount protein (50µg) were separated
by SDS-PAGE and followed by immunoblotting. The blot was probed with antiphospho-ERK5 and anti-ERK5 antibody. Quantification of ERK5 phosphorylation
was performed by scanning densitometry and ERK15 phosphorylation intensity
was normalized with ERK5 intensity. The values were means ± SEM of at least
four independent experiments and were plotted relative 0 min without ET-1
stimulation. Asterisks indicate significant differences of values compared with 0
min (P < 0.05, Dunnet’s test).
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Figure 51: ET-1 induced FAK-S910 phosphorylation is through ERK5.
NRVM were infected with empty virus (50moi, 48hr) or Adv-dnERK5 (10-50moi,
48h) and then stimulated with ET-1 (100nM, 30min). Lysates (50 µg total protein)
were separated by SDS-PAGE followed by Western blotting with anti-FAK-S910,
anti-FAK, anti-GAPDH and anti-Src antibodies. Top, representative blots are
depicted. Bottom, quantitative analysis of at least four independent Western
blotting experiments is depicted. Quantification of FAK phosphorylation at S910
was performed by scanning densitometry and FAK-S910 phosphorylation
intensity were normalized with total FAK intensity. The values were means ±
SEM of at least four independent experiments and were plotted relative Adv-βgal plus ET-1 stimulation. Asterisks indicate significant differences of values
compared with Adv-β-gal plus ET-1 stimulation (P < 0.05, Dunnet’s test).
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Figure 52: caMEK5 is sufficient to induce FAK-S910 phosphorylation.
NRVM were infected with empty virus (20moi) or Adv-caMEK5 (5-20 moi) for 48h.
NRVM were washed twice with ice-cold PBS and sonicated in lysis buffer. Cell
extracts (50µg total protein) were separated by SDS-PAGE followed by Western
blotting with anti-FAK-S910, anti-FAK and HA antibody, as indicated.
Quantification of FAK phosphorylation at S910 was performed by scanning
densitometry and FAK-S910 phosphorylation intensity were normalized with total
FAK intensity.

The values were means ± SEM of at least four independent

experiments and were plotted relative Adv-β-gal. Asterisks indicate significant
differences of values compared with Adv-β-gal (P < 0.05, Dunnet’s test).
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18. ET-1 induced ERK5 phosphorylation is through Src, but
not Fyn.
Src has been shown to be involved in ERK5 activation in other cell types.
(Sun et al., 2003) To examine whether Src is involved in ET-1 induced ERK5
phosphorylation, NRVM were pre-treated (1h) with PP2 or PP3; or infected with
Adv expressing dnSrc or dnFyn (50moi, 48h), and then stimulated with 100nM
ET-1 for 10min. ET-1 induced ERK5 activitation was dependent on Src, as
pretreating NRVM with PP2 (Figure 53) or overexpressing dnSrc (Figure 54) both
blocked ET-1 induced ERK5 phosphorylation. Surprisingly, overexpression of
dnFyn did not inhibit ET-1 induced ERK5 phosphorylation (Figure 55). I conclude
from this experiment that Fyn may be involved in a different downstream
signaling pathway that regulates FAK-S910 phosphorylation. Nevertheless, these
results indicate that ET-1 induced ERK5 phosphorylation is through Src but not
Fyn.
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Figure 53: The SFK inhibitor PP2 inhibits ET-1 induced ERK5
phosphorylation. NRVM were pretreated (1h) with PP2 (25µM) or PP3 (25µM)
and then stimulated with ET-1 (100nM, 10min). NRVM were washed twice with
ice-cold PBS and sonicated in lysis buffer. Lysates (50 µg total protein) were
separated by SDS-PAGE followed by Western blotting with anti-FAK-S910, antiFAK antibodies, anti-phospho-ERK5 and anti-ERK5. Top, representative blots
are depicted. Bottom, quantitative analysis of at least four independent Western
blotting experiments is depicted. Data are the means±SEM, and are expressed
as the percentage of ET-1 stimulation in the absence of antagonists.
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Figure 54: Overexpression dnSrc attenuated ET-1 induced ERK5
phosphorylation. NRVM were infected with empty virus (50moi, 48hr) and AdvdnSrc (50moi, 48h) and then stimulated with ET-1 (100nM, 10min). Lysates (50
µg total protein) were separated by SDS-PAGE followed by Western blotting with
anti-phospho-ERK5 anti-ERK5, anti-Src and anti-GAPDH antibodies. Top,
representative blots are depicted. Bottom, quantitative analysis of at least four
independent Western blotting experiments is depicted. Quantification of ERK5
phosphorylation

was

performed

by

scanning

densitometry

and

ERK5

phosphorylation intensity were normalized with total FAK intensity. The values
were means ± SEM of at least four independent experiments and were plotted
relative empty virus plus ET-1 stimulation. Asterisks indicate significant
differences of values compared with empty virus empty virus plus ET-1
stimulation (P < 0.05, Dunnet).
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Figure 55: Overexpression of dnFyn does not block ET-1 induced
ERK5 phosphorylation. NRVM were infected with empty virus (50moi, 48hr)
and Adv-dnSrc (10-50moi, 48h) and then stimulated with ET-1 (100nM, 10min).
Lysates (50 µg total protein) were separated by SDS-PAGE followed by Western
blotting with anti-phospho-ERK 5, anti-ERK5 and anti-Fyn antibodies.

19.

PKCδ
δ

is

also

involved

in

ET-1

induced

130
ERK5

phosphorylation.
Previous studies have also shown that ERK5 activity is regulated by
PKCs.(Geng et al., 2009; Villa-Moruzzi, 2007) To investigate whether PKCδ was
also involved in ET-1 induced ERK5 phosphorylation, cells were infected with
dnPKCδ

(50moi,

48h)

then

stimulated

with

100nM

ET-1

for

10min.

Overexpression of dnPKCδ significantly attenuated ET-1 induced ERK5
activation (Figure 56). These results show that PKCδ may also beinvolved in ET1 induced ERK5 phosphorylation.
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Figure 56: Overexpression dnPKCδ
δ attenuated ET-1 induced ERK5
phosphorylation. NRVM were infected with empty virus (50moi, 48hr) and AdvdnPKCδ (50moi, 48h) and then stimulated with ET-1 (100nM, 10min). Lysates
(50 µg total protein) were separated by SDS-PAGE followed by Western blotting
with anti-PKCδ, anti-GAPDH, anti-phospho-ERK5 and anti-ERK5 antibodies.
Top, representative blots are depicted. Bottom, quantitative analysis of at least
four independent Western blotting experiments is depicted. Quantification of
ERK5 phosphorylation were performed by scanning densitometry and ERK5
phosphorylation intensity was normalized with total FAK intensity. The values
were means ± SEM of at least four independent experiments and were plotted
relative empty virus plus ET-1 stimulation. Asterisks indicate significant
differences of values compared with empty virus empty virus plus ET-1
stimulation (P < 0.05, Dunnet’s test).

132
20. ERK5 in nonfailing LV myocardium and in dilated
cardiomyopathy.
Finally, I also examined the phosphorylation status of ERK5 in nonfailing
human LV tissue, and in LV tissue from patients undergoing cardiac
transplantation for DCM. ERK5 phosphorylation was undetectable in both
nonfailing and DCM samples. As seen in Figure 57, however, ERK5 expression
levels were significantly reduced by ~70% (P<0.05) in DCM as compared to
nonfailing, control hearts. This result suggests that the inhibition of FAK-S910
phosphorylation in DCM samples (Figure 13) may be related to ERK5
downregulation in these diseased human hearts.
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Figure 57. ERK5 in nonfailing LV myocardium and in dilated
cardiomyopathy. Human LV tissue extracts (75µg total protein) from nonfailing
(GOH; n=12) and DCM (n=12) hearts were separated by SDS-PAGE followed by
Western blotting with total anti-ERK5 and anti-GAPDH antibodies, as indicated.
Representative Western blots (left) and quantitative analysis of ERK5 expression
at each site (right) are depicted. Values shown as bars are the mean ± SEM of at
least four independent experiments and are expressed as the fold increases of
phosphorylation above control values. Asterisks indicate significant differences of
values compared with nonfalling (P < 0.05, T-test).
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21. Summary of ET-1 induced FAK-S910 phosphorylation.
Overall,

these

results

indicate

that

ET-1

induced

FAK-S910

phosphorylation was predominantly mediated by activation of the ETAR. ETAR
receptor activation led to downstream activation of PKCδ and the SFKs, Src and
Fyn. PKCδ regulates FAK-S910 phosphorylation through both Raf-1-MEK1/2ERK1/2 and MEK5-ERK5 pathways. Src can also activate a MEK5-ERK5
signaling pathway that induces FAK-S910 phosphorylation. Finally, Fyn may also
be involved in ET-1 induced FAK-S910 phosphorylation, but the downstream
signaling pathway(s) remain unclear. This complex signaling web leading to FAKS910 phosphorylation is depicted in Figure 58.
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Figure 58: ET-1 induced of FAK-S910 phosphorylation ET-1 induced
FAK-S910 phosphorylation is mediated through the ETAR, which subsequently
activates PKCδ-Raf-1-MEK1/2-ERK1/2, PKCδ-MEK5-ERK5 and Src-MEK5ERK5 signaling pathways.
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22. FAK tyrosine phosphorylation is modulated by FAK-S910
phosphorylation.
The S910 phosphorylation site is adjacent to the FAT sequence in FAK
(residues 916-1004), and phosphorylation at the S910 site might be involved in
regulating the structural integrity of the FAT domain. FAK-S910 phosphorylation
may therefore regulate the function of the FAT domain in targeting FAK to focal
adhesions, and in regulating its susceptibility for tyrosine phosphorylation within
its C-terminus. Several studies have been demonstrated that FAT domain
structural integrity is important in regulating FAK-Y925 phosphorylation.(Cooley
et al., 2000; Prutzman et al., 2004)To investigate whether S910 phosphorylation
is involved in regulating FAK tyrosine phosphorylation, I mutated FAK-S910 to
alanine (S910A-FAK) to render the mutant nonphosphorylatable at this site, and
used adenoviral-mediated overexpression of 3XFLAG-tagged wildtype FAK (WTFAK) and S910A-FAK in NRVM. Cells were infected (10 moi, 48h) and then
stimulated with ET-1 (100nM; 60 min). To determine if FAK tyrosine
phosphorylation was altered by the mutational status of S910, I then performed
co-immunoprecipitation and Western blotting, by first immunoprecipitating NRVM
extracts with anti-FLAG antibody, and then probing the immunoprecipitate with
different phosphotyrosine-specific antibodies. As seen in Figure 59, WT-FAK wss
phosphorylated at Y397, Y577, Y861 and Y925 under the basal conditions. After
ET-1 stimulation for 60min, FAK Y925 phosphorylation was significantly
increased. When I mutated Serine 910 to Alanine, the phosphorylation of Y577
and Y925 was significant decreased under the basal conditions, and S910A

137
mutation also prevented ET-1 induced FAK Y925 phosphorylation. These results
suggest that FAK-S910 phosphorylation is some how involved in regulating the
FAK-Y577 and FAK-Y925 phosphorylation sites.
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Figure 59: FAK tyrosine phosphorylation is modulated by FAK-S910
phosphorylation. NRVM were infected with Adv-WT-FAK or Adv-S910A-FAK
(10moi, 48h) and then stimulated with ET-1 (100nM, 1h). Cell extracts (300 µg
total protein) were co-immunoprecipitated with anti–FLAG and immunoblots were
probed with anti–FLAG, anti-FAK-Y397, anti-FAK-Y577 anti-FAK-Y861 and antiFAK-Y925 antibodies. Representative Western blots (left) and quantitative
analysis of FAK tyrosine phosphorylation at each site (right) is depicted. Values
shown as bars are the mean ± SEM of at least four independent experiments and
are expressed as the fold increases of phosphorylation above control values.
Asterisks indicate significant differences of values compared with control WTFAK (P < 0.05, Dunnet’s test).
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23 Paxillin and FAK interaction is regulated by FAK-S910
phosphorylation.
A previous study in NIH-3T3 fibroblasts showed that mutation of FAK at
S910 increased the paxillin–FAK interaction.(Hunger-Glaser et al., 2003). To
investigate whether FAK-S910 phosphorylation is involved in regulating the
paxillin-FAK interaction in NRVM, cells were infected with WT-FAK or S910AFAK (10 moi, 48h); and then stimulated with ET-1 (100nM; 60 min). To determine
if paxillin interacted with FAK, I then performed co-immunoprecipitation and
Western blotting, first by immunoprecipitating NRVM extracts with anti-FLAG or
anti-paxillin antibody and then probing the immunoprecipitates for paxillin or
FLAG. As seen in Figure 60, WT-FAK was phosphorylated at S910, and was
associated with paxillin under basal conditions. When I mutated S910 to alanine,
I rendered this site nonphosphorylatable, and also increased the interaction
between FAK and paxillin. After ET-1 stimulation, the WT-FAK-paxillin interaction
was not changed, but there was substantially more interaction between S910AFAK and paxillin. Similarly, co-immunoprecipitation with paxillin antibody
revealed an increase in paxillin association with S910A-FAK, but not WT-FAK.
Additionally, there was more WT-FAK phosphorylated at S910 in the coimmunoprecipation complex. These data indicate that FAK-S910 phosphorylation
is important for regulating the steady-state interaction of FAK and paxillin,
perhaps by altering the structural integrity of the FAK FAT domain.
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Figure 60: FAK and paxillin interaction is regulated by FAK-S910
phosphorylation. NRVM were infected with Adv-WT-FAK or Adv-S910A-FAK
(10moi, 48h) and then stimulated with ET-1 (100nM, 1h). Cell extracts (300 µg
total proteins) were co-immunoprecipitated with anti–FLAG or anti-paxillin
antibodies and immunoblots were probed with anti–FLAG, anti-Hic-5, anti-paxillin
or anti-FAK-S910 antibodies.
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24. FAK-S910 phosphorylation is important in regulating
paxillin stability.
My co-immunoprecipitation experiments demonstrate that FAK-S910
phosphorylation is important in regulating the steady-state FAK-paxillin
interaction. Next, I examined the role of FAK-S910 phosphorylation in regulating
paxillin’s stability within costameres. The kinetics of paxillin binding to other
proteins within costameres was interrogated by using TIRF and FRAP. Studies
were conducted in cells overexpressing WT-FAK or S910A-FAK (Figure 61).
GFP-tagged paxillin was then overexpressed, and used to trace the dynamic
exchange of paxillin within costameres by the combined use of TIRF-microscopy
and FRAP analysis.(Koshman et al., 2010a; Koshman et al., 2010bh) If FAKS910 phosphorylation is important in stabilizing paxillin within the focal adhesion
complex, then GFP-paxillin kFRAP should decrease, indicating an increase in the
half-life (t1/2) of paxillin within these structures. Curve-fitting analysis of GFPpaxillin containing focal adhesion complexes revealed a significant decrease in
KFRAP (or increase in t1/2) in S910A-FAK overexpressing cells as compared to
WT-FAK (Figure 62). kFRAP also significantly decreased in WT-FAK expressing
cells treated with ET-1. Surprisingly, when cells were treated with ET-1, there
was no significant difference between WT-FAK and S910A-FAK. These data
indicate that FAK-S910 phosphorylation is important in regulating paxillin binding
kinetics within focal adhesion complexes under the basal conditions, but when
cells were treated with ET-1, the FAK-S910A mutation did not attenuate Kfrap for
paxillin.
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Overall, from my co-immunoprecipitation and TIRF-FRAP studies, I find
that FAK-S910 phosphorylation is important in regulating the interaction of FAK
and paxillin. When I co-immunoprecipitated paxillin, I could still detect
nonphosphorylatable FAK in the co-immunoprecipitation complex. These results
raise the possibility that FAK-S910 phosphorylation may not be directly involved
in regulating the FAK-paxillin interaction, but rather FAK phosphorylation at this
site may affect conformational rearrangements that occur within the FAT domain.
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Figure 61: TIRF-FRAP of GFP-paxillin in NRVM. NRVM were infected
with Adv-WT-FAK or Adv-S910A-FAK (10moi, 24h) and then were infected with
Adv-GFP-paxillin (10moi) for an additional 24h. Cells were stimulated with ET-1
(100nM, 1h) and GFP-paxillin localized to the cell membrane by TIRF
microscopy was subjected to FRAP analysis. The position of the laser beam is
represented by the circle. Images were acquired every 200 milliseconds before,
during, and up to 35 sec after the photobleaching flash. Representative images
at 0, 3, 6, and 35 sec after photobleaching are depicted.
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Figure

62: KFRAP

of GFP-paxillin

is regulated by FAK-S910

phosphorylation. NRVM were infected with Adv-WT-FAK or Adv-S910A-FAK
(10moi, 24h) and then were infected with Adv-GFP-paxillin (10moi) for an
additional 24h. Cells were stimulated with ET-1 (100nM, 1h) and GFP-paxillin
localized to the cell membrane by TIRF microscopy was subjected to FRAP
analysis. The position of the laser beam is represented by the circle. Images
were acquired every 25 milliseconds before, during, and up to 16 sec after the
photobleaching flash. Data are means±SEM for curve fitting analysis of WT-FAK
or S910A-FAK infected cells with or without ET-1 stimulation. Average KFRAP and
t1/2 values for 3 independent experiments of 20 individual cells (i.e., 60 individual
TIRF-FRAP recordings) were compared. *P<0.05 vs. unstimulated, WT-FAK
infected cells by 1-way ANOVA followed by Dunnet’s test.
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25 Tyrosine phosphorylation of FAK is also important in
regulating FAK and paxillin interaction.
The FAT domain of FAK (residues 916-1004) also contains a tyrosine
phosphorylation site (Y925). Once phosphorylated, the FAK-Y925 site can form a
SH2 binding site for GRB2, and the subsequent interaction of FAK with GRB2
might then displace paxillin.(Dixon et al., 2004; Prutzman et al., 2004) Therefore,
I examined whether FAK-Y925 phosphorylation affected the FAK-paxillin
interaction. Cells were pre-treated with PP2 (25µM, 1h) then stimulated with
100nM ET-1 for 60min. To determine if paxillin interacted with FAK, I then
performed

co-immunoprecipitation

and

Western

blotting,

first

by

immunoprecipitating NRVM extracts with anti-FAK antibody and then probing for
paxillin. As seen in Figure 63, when cells were treated with ET-1, the FAK-paxillin
interaction decreased. However, when cells were pre-treated with PP2 and then
stimulated with ET-1, the paxillin-FAK interaction was enhanced. These data
indicate that FAK-Y925 phosphorylation is also important in regulating the paxillin
and FAK interaction.
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Figure 63: The FAK and paxillin interaction is regulated by FAK
tyrosine phosphorylation. NRVM were pretreated with PP2 (25µM, 1h) and
then stimulated with ET-1 (100nM, 60min). NRVM were washed twice with icecold PBS and sonicated in lysis buffer. Cell extracts (300 µg total protein) were
co-immunoprecipitated with anti–FAK antibodies and immunoblots were probed
with anti-paxillin and anti-FAK-S910 antibodies.
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26 FAK-S910 phosphorylation is important in regulating the
paxillin-vinculin interaction.
X-ray crystallographic studies have shown that C-terminal domain of
vinculin and the FAK FAT domain share considerable structural similarity, and
the binding sites for both proteins on paxillin are overlapping. The binding sites
on paxillin contain repeats of leucine-rich sequences, named LD motifs(Bakolitsa
et al., 1999; Hayashi et al., 2002a; Tumbarello et al., 2002; Turner, 2000; Turner
et al., 1999) Other studies have also shown that the myosin II–dependent
recruitment of vinculin to FAs is mediated by FAK phosphorylation of paxillin,
which creates binding sites in FAs for vinculin to drive FA maturation.(Pasapera
et al., 2010) My studies have revealed that FAK-S910 phosphorylation is
important in regulating the FAK-paxillin interaction. I now suggest that FAK-S910
phosphorylation is also important in modulating the paxillin-vinculin interaction.
To investigate if FAK-S910 phosphorylation is involved in modulating the
paxillin-vinculin interaction, I used HEK-293 cells as a model system. First HEK293 cells were co-transfected with expression plasmids for GFP-paxillin and
vinculin, and at same time I also transfected the cells with WT-FAK or S910AFAK for 48h. Cells were then stimulated with ET-1 (100nM; 60 min). To
determine if FAK-S910 phosphorylation affected the paxillin-vinculin interaction, I
then

performed

co-immunoprecipitation

and

Western

blotting,

by

immunoprecipitating cell extracts with anti-vinculin or anti-paxillin antibody and
probing for paxillin or FLAG. As seen in Figure 64, under basal conditions or in
cells expressing WT-FAK, vinculin was associated with paxillin, and this
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interaction was significantly increased after ET-1 stimulation. In contrast, cells
transfected with S910A-FAK demonstrated significantly reduced paxillin-vinculin
interaction under the basal conditions, or in response to ET-1 stimulation.
Similarly, co-immunoprecipitation with paxillin antibody revealed an increase in
vinculin association with paxillin following ET-1 stimulation. Overexpression
S910A-FAK also reduced paxillin-vinculin interaction.
In further support of these results, NRVM were infected with WT-FAK or
S910A-FAK (10 moi, 48h); and then stimulated with ET-1 (100nM; 60 min). I then
performed co-immunoprecipitation and Western blotting, by immunoprecipitating
NRVM extracts with anti-vinculin antibody and probing for paxillin. As seen in
Figure 65, under basal conditions or in cells expressing WT-FAK, vinculin was
associated with paxillin, and this interaction was significantly increased after ET-1
stimulation. In contrast, cells expressing S910A-FAK had significantly reduced
paxillin-vinculin interaction under the basal conditions, or following ET-1
stimulation. These results suggest that FAK-S910 phosphorylation is also
important in regulating the paxillin-vinculin interaction.
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Figure 64: Vinculin and paxillin interaction is modulated by FAKS910 phosphorylation in HEK293 cells. HEK 293 cells were transfected with
GFP-paxillin and YFP-vinculin, and at the same time were also transfected with
WT-FAK or S910A-FAK expression plasmids. After 48h, cells were then
stimulated with ET-1 (100nM, 1h). Cell extracts (500 µg total proteins) were coimmunoprecipitated with anti–vinculin or anti-paxillin antibodies and immunoblots
were probed with anti–paxillin and anti-vinculin antibodies (right panel). Total cell
lysates (50 µg total protein) were separated by SDS-PAGE followed by Western
blotting with anti-FLAG, anti-FAK-S910, anti-vinculin, anti-paxillin, anti-pTyr and
anti-GAPDH antibodies.
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Figure 65: Vinculin and paxillin interaction is modulated by FAKS910 phosphorylation in NRVM. NRVM were infected with Adv-WT-FAK or
Adv-S910A-FAK (10moi, 48h) and then stimulated with ET-1 (100nM, 1h). Cell
extracts (500 µg total protein) were co-immunoprecipitated with anti–vinculin
antibodies and immunoblots were probed with anti–vinculin or anti-paxillin
antibodies. Total cell lysates (50 µg total protein) were separated by SDS-PAGE
followed by Western blotting with anti-FLAG, anti-FAK-S910, anti-vinculin, antipaxillin, anti-pTyr, anti-Y118-paxillin and anti-GAPDH antibodies.
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27. FAK is important in ET-1 induced sarcomere reorganization.
Previous studies have also shown that overexpression of the FAT domain
of FAK disrupted sarcomere structure in NRVM.(Eble et al., 2000b; KovacicMilivojevic et al., 2001) Knocking down FAK with shRNAs also attenuated
costmerogenesis and myofibrillogenesis in differentiating skeletal muscle cells.
To test the importance of normal FAK signaling in costamere structure, I used an
shRNA approach to reduce FAK levels. Cells were infected with Adv-FAK-1
shRNA and Adv-FAK-2 shRNA mixture (20moi for each virus, 48h) or Adv-Luc
shRNA (40moi, 48h) and then stimulated with 100nM ET-1 for 48h. Three days
after infection, the level of FAK was dramatically downregulated in NRVM
infected with FAK shRNA as compared to controls. After 3 days, cells were
stained for F-actin with rhodamine phalloidin. Downregulation of FAK disrupted
sarcomeric structure in NRVM as compared to cells infected with Adv-Luc
shRNA.(Figure 66).
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.

Figure

66:

FAK

is

important

in

ET-1

induced

sarcomere

reorganization. NRVM were infected with Adv-FAK-1 shRNA and Adv-FAK-2
shRNA mixture (20moi for each virus, 48h) or Adv-Luc shRNA (40moi, 48h) and
then stimulated with 100nM ET-1 for 48h. Lysates (50 µg total protein) were
separated by SDS-PAGE followed by Western blotting with anti-FAK and antiGAPDH antibodies (upper right). Cells were fixed, permeabilized and stained for
F-actin (with Rhodamine Phalloidin, red) and for GFP (green).
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28 FAK-S910 phosphorylation is important for maintaining zbody stability.
During costamerogenesis and myofibrillogenesis in cardiomyocytes, one
important step is recruiting α-actinin to the costamere region.(Sanger et al., 2010)
Therefore, I examined if FAK-S910 phosphorylation affected the formation of a
FAK-α-actinin complex, and by inference the maintenance of cardiomyocyte
costamere assembly. To examine the role of FAK-S910 phosphorylation in
stabilizing costameres, I examined the kinetics of α-actinin binding using FRAP in
cells overexpressing WT-FAK or S910A-FAK (Figure 67). YFP-tagged α-actinin
was used as a marker for costamere assembly at the cell-substratum interface,
which was imaged by TIRF-microscopy. If FAK-S910 phosphorylation is
important in stabilizing α-actinin within costameric structures, then YFP-α-actinin
kFRAP should decrease, indicating an increase in the half-life (t1/2) of α-actinin
within these structures. Figure 67 depicts a representative TIRF-FRAP
experiment. Single-exponential, curve-fitting analysis of YFP-α-actinin containing
costameres revealed no difference in kFRAP (or t1/2) between WT-FAK and S910AFAK overexpressing cells (Figure 68). However, when NRVM were treated with
ET-1, KFRAP significantly decreased in WT-FAK, but not in S910A-FAK cells,
resulting in an increase in the half-life of α-actinin within costameres. Overall,
these results indicate that FAK-S910 phosphorylation is important in stabilizing αactinin within costameres.
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Figure 67: TIRF-FRAP of α-actinin in NRVM. NRVM were infected with
Adv-WT-FAK or Adv-S910A-FAK (10moi, 24h) and then were infected with AdvYFP-α-actinin (10moi) for an additional 24h. Cells were stimulated with ET-1
(100nM, 1h) and YFP-α-actinin localized to the cell membrane by TIRFmicroscopy was subjected to FRAP analysis. The position of the laser beam is
represented by the circle. Images were acquired every 25 milliseconds before,
during, and up to 16 sec after the photobleaching flash. Representative images
at 0, 1, 3, and 8 sec after photobleaching are depicted.
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Figure

68:

α-actinin

stability

was

regulated

by

FAK-S910

phosphorylation. NRVM were infected with Adv-WT-FAK or Adv-S910A-FAK
(10moi, 24h) and then were infected with Adv-YFP α-actinin (10moi) for an
additional 24h. Cells were stimulated with ET-1 (100nM, 1h) and YFP α-actinin
localized to the cell membrane by TIRF microscopy was subjected to FRAP
analysis. The position of the laser beam is represented by the circle. Images
were acquired every 25 milliseconds before, during, and up to 16 sec after the
photobleaching flash. Data are means±SEM for curve fitting analysis of WT-FAK
or S910A-FAK infected cells with or without ET-1 stimulation. Average KFRAP and
t1/2 values for 3 independent experiments of 20 individual cells (i.e., 60 individual
TIRF-FRAP recordings) were compared. *P<0.05 vs. unstimulated, WT-FAK
infected cells by 1-way ANOVA followed by Dunnet’s test; #P<0.05 vs. ET-1
stimulated, WT-FAK infected cells 1-way ANOVA followed by Student-NewmanKeuls test.
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29 FAK-S910 phosphorylation is important for NRVM sarcomere
assembly.
Increased cytoskeletal reorganization and sarcomere assembly are
characteristics of cardiomyocyte hypertrophy.(Myklebust et al., 1978; Samarel,
1993) Therefore, to determine the effect of FAK-S910 phosphorylation on
cytoskeletal reorganization and sarcomere assembly, NRVM were infected with
Adv-WT-FAK or Adv-S910A-FAK (10moi, 24h) and then stimulated with ET-1
(100nM; 48h). ET-1 induced cytoskeletal reorganization was first examined by Factin staining (Figure 69). Although there was no apparent difference in
sarcomere assembly in unstimulated cells, ET-1 stimulation induced an obvious
increase in cytoskeletal reorganization in WT-FAK cells, but not in S910A-FAK
expressing cardiomyocytes.

Next

I

examined

the

effect of

FAK-S910

phosphorylation on sarcomere assembly by α-actinin and F-actin staining. There
was no apparent difference in sarcomere assembly in unstimulated cells. After
ET-1 stimulation, there was an obvious increase in sarcomere assembly in WTFAK cells, but in S910A-FAK expressing cardiomyocytes the α-actinin staining
was diffusely distributed in the cytoplasm and there were fewer, less-organized
sarcomeres (Figure 69 and 70).
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Figure 69: FAK-S910 was important in ET-1 induced sarcomere
reorganization. NRVM were infected with Adv-WT-FAK and Adv-S910A-FAK
(10moi, 48h) and then stimulated with 100nM ET-1 for 48h. Cells were fixed,
permeabilized and stained for F-actin (with Rhodamine Phalloidin, red) and for
FLAG (green). Magnified images of boxed areas around bundles of sarcomeres
are shown in the inserts. Bar=10 µm.
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Figure 70: ET-1 induced sarcomere reorganization is regulated by
FAK-S910 phosphorylation. NRVM were infected with Adv-WT-FAK and AdvS910A-FAK (10moi, 48h) and then stimulated with 100nM ET-1 for 48h. Cells
were fixed, permeabilized and stained for F-actin (with Rhodamine Phalloidin,
red), for FLAG (FITC, green) and for α-actinin (Alexa flour 350, blue) Magnified
images of boxed areas around bundles of sarcomeres are shown in the inserts.
Bar=10 µm.

30

FAK-S910

phosphorylation

is

important

for

159
NRVM

spreading.
Increased cell spreading, cytoskeletal reorganization and sarcomere
assembly are all characteristics of cardiomyocyte hypertrophy.(Chien et al., 1991)
Next I examined the effects WT-FAK and S910A-FAK overexpression on NRVM
cell surface area under basal conditions, and in response to ET-1. NRVM were
infected with Adv-WT-FAK or Adv-S910A-FAK (10moi, 24h) and then stimulated
with ET-1 (100nM; 48h). Cells were then dye-loaded with BCECF and viewed
under an epifluorescence microscope in order to visualize the margins of the cell
membrane. As seen in Figure 71, chronic ET treatment of WT-FAK infected
NRVM resulted in a near 1.5-fold increase in cell surface area. Conversely, the
average surface area of S910A-FAK overexpressing cells was similar to WT-FAK
cells, but S910A-FAK overexpression prevented the ET-induced increase in
surface area (Figure 71). Overall, these data indicate that FAK-S910
phosphorylation is important in regulating specific aspects of ET-1 induced
cardiomyocyte hypertrophy.
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Figure 71: ET-1 induced spreading is regulated by FAK-S910
phosphorylation. NRVM were infected with Adv-WT-FAK or Adv-S910A FAK
(10moi, 24h) and then stimulated with ET-1 (100nM, 48h). Cell surface area was
then measured by BCECF dye loading and image analysis. Data are
means±SEM of 250-400 cells from each treatment group, normalized to the
surface area of untreated WT-FAK expressing cells. *P<0.05 vs. unstimulated,
WT-FAK infected cells by 1-way ANOVA on Ranks followed by Dunnet’s test;
#

P<0.05 vs. ET-1 stimulated, WT-FAK infected cells 1-way ANOVA followed by

Student-Newman-Keuls test.

CHAPTER FIVE
DISCUSSION
1. ET-1 induced FAK serine phosphorylation
Different neurohumoral factors such as ET-1, AngII and PE have been
previously demonstrated to induce a rapid increase in FAK tyrosine
phosphorylation in cardiomyocytes. However, the regulation of FAK serine
phosphorylation by neurohumoral factors is still not clear. In the SHHF rat,
studies have shown a significant increase in FAK-S722 and FAK-S910
phosphorylation in freshly isolated LV cardiomyocytes.(Yi et al., 2003; Zhong et
al., 2008) However, these investigators did not identify the responsible signaling
pathways, or the functional significance of FAK serine phosphorylation in these
hypertensive animals. In my studies, I found that that the same hypertrophic
agonists that induce FAK tyrosine phosphorylation also induce FAK-S910
phosphorylation. FAK-S910 phosphorylation is mediated through GPCRs and
RTKs, which share the ability to activate the downstream MAPKs, ERK1/2 and
ERK5. Although my attention was focused on the S910 site, it is clear that other
serine sites are also phosphorylated in cardiomyocytes. For instance, I found that
the S722 site was constitutively phosphorylated in both human LV tissue and
cultured NRVM. FAK-S732 and FAK-S843 phosphorylations were slightly
increased by ET-1 stimulation. Importantly, my studies are also consistent with
161
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previous studies conducted in Swiss 3T3 fibroblasts, intestinal epithelial cells and
colorectal cancer cells.(Hunger-Glaser et al., 2004; Hunger-Glaser et al., 2003;
Jiang et al., 2007) These reports indicate that FAK-S910 and FAK-S843
phosphorylations are regulated by both GPCRs and RTKs.
As indicated above, my studies have shown that the FAK-S722 site was
constitutively phosphorylated in NRVM. Bianchi et al have shown that FAK-S722
is regulated by the serine kinase GSK3β in fibroblasts. GSK3β plays an important
role in the development of cardiac hypertrophy. (Kerkela et al., 2007; Markou et
al., 2008; Sugden et al., 2008) These studies suggest that GSK3β is
constitutively active under basal conditions, and is a negative regulator of
cardiomyocyte hypertrophy. Many hypertrophic stimuli can activate PKB/AKT,
which phosphorylates and inactivates GSK3ß, thereby relieving its inhibitory
effect(Obata et al., 2000). Based on these observations, FAK-S722 might be
constitutively phosphorylated by GSK3β in NRVM. However, ET-1 is a potent
activator of the PKB/AKT pathway, and can reduce GSK3β activity by
phosphorylating the kinase at its S9 residue(Haq et al., 2000; Morisco et al.,
2000).

Surprisingly,

when

NRVM

were

treated

with

ET-1,

FAK-S722

phosphorylation was not attenuated, suggesting that other serine kinases may be
involved. Future studies will be necessary to determine which kinases are
responsible, and to determine its functional significance.
Previous studies have also shown that FAK-S732 is regulated by CDK5
and ROCK in other cell types.(Le Boeuf et al., 2006; Xie and Tsai, 2004) FAKS732 phosphorylation has been implicated in regulating centrosome function and
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microtubule organization.(Park et al., 2009) The CDK family of protein kinases
(CDK1, CDK2, CDK4, and CDK5) is required for cell-cycle progression, and their
expression abruptly declines to almost undetectable levels after 10-20 days of
age in cardiomyocytes.(Brooks et al., 1998) I was able to detect some degree of
FAK-S732 phosphorylation in both NRVM and human LV tissue samples, but for
this reason, its phosphorylation was probably not dependent on CDKs. Of note,
S732 also can be regulated by ROCK, and our lab has previously demonstrated
that ET-1 or PKCε can induce FAK-Y397 phosphorylation via a ROCKdependent pathway.(Heidkamp et al., 2003) Here I have shown that ET-1 can
also induce FAK-S732 phosphorylation, which conceivably was mediated by ET1 induced activation of ROCK.

Additional studies using ROCK inhibitors,

dnROCK and ROCK siRNAs should clarify this issue.
Different agonists such as AngII, LPA and EGF can induce FAK-S843
phosphorylation in nonmusclecell types, which is regulated by Ca2+/calmodulindependent kinase II (CaMKII).(Jiang et al., 2007) Previous studies have
suggested that Ca2+ plays a critical role in ET-1 induced cardiomyocyte
hypertrophy by activating CaMKII- and calcineurin-dependent pathways.(Zhu et
al., 2000) Here, I have demonstrated that ET-1 can induce FAK-S843
phosphorylation, and it is interesting to speculate that CaMKII is involved. This
phosphorylation may be particularly important to cardiomyocyte function, as it
was substantially decreased in end-stage DCM tissue samples.

2.

PKC

isoenzymes

in

ET-1

induced
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FAK-S910

phosphorylation
Cardiomyocytes contain both ETAR and ETBR, and the ETAR is the major
isoform that is responsible for ET-1 induced hypertrophy.(Ito et al., 1994) ETAR is
a Gq/11-coupled GPCR, which activates phospholipase C-mediated production of
IP3. IP3 triggers the release of Ca2+ from internal stores, and the byproduct DAG,
directly activates classical and novel PKCs.(Irons et al., 1993; Sugden et al.,
1993) PKC isoenzymes have been demonstrated to be important regulators of
cardiac hypertrophy and ventricular remodeling. PKCs, including PKCδ, are
activated and/or up-regulated in numerous models of cardiac hypertrophy. In
NRVM, PMA-sensitive PKC isoenzymes are targeted to distinct subcellular
locations.(Mochly-Rosen et al., 1990; Rybin and Steinberg, 1997; Rybin et al.,
1997; Rybin and Steinberg, 1994) Under basal conditions, PKCα and PKCεare
located in the cytosol, and they translocate to the perinuclear region (PKCα) and
sarcomeres (PKCε) upon activation.(Braz et al., 2002; Disatnik and Rando, 1999)
PKCδ translocates from the nucleus to the fibrillar cytoskeleton, perinucleus and
focal contacts.(Disatnik et al., 1994) Our lab has also demonstrated that PKCδ
(along with PKCε) are involved in the down-regulation of sarco(endo)plasmic
reticulum Ca2+-ATPase(SERCA2) expression, a characteristic feature of the
hypertrophic phenotype. PKCδ overexpression is also reported to activate JNKs
and

p38MAPK,

promote

cell

detachment,

and

induce

cardiomyocyte

apoptosis.(Heidkamp et al., 2001; Porter et al., 2003; Strait et al., 2001; Strait
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and Samarel, 2000)
PKCδ and FAK are both involved in the regulation of several common
endothelial cell functions. Furthermore PKCδ and PKCε can be activated by
integrin engagement, leading to its translocation from the cytosol to the cell
membrane.(Besson et al., 2002; Hendey et al., 2002; Loeser et al., 2003)
Inhibition of PKC isoenzymes has been shown to prevent cell spreading and
migration.(Chae et al., 2010; Kurkinen et al., 2001; Miranti et al., 1999; Wang et
al., 2002) In rat embryonic fibroblasts, PKCδ has been shown to be one of the
first components recruited to newly formed focal adhesions, rapidly following the
recruitment of FAK.(Barry and Critchley, 1994) This was accompanied by a
significant

increase

in

the

number

of

FAK-based

focal

adhesion

contacts.(Harrington et al., 2003)
Rybin et al. have also demonstrated that PE causes the translocation of
PKCα, PKCδ and PKCε to caveolae, and induces a local increase in ERK1/2
activity.(Rybin et al., 1999) ET-1 causes a rapid, ETAR-mediated translocation of
PKCδ
δand

PKCεεand

subsequent

stimulation

of

Raf-1-MEK1/2-

ERK1/2.(Chiloeches et al., 1999; Clerk et al., 1994) I showed that treatment of
NRVM with PMA, a direct activator of PKCs, induced FAK-S910 phosphorylation,
and treatment with selective PKC inhibitors or dnPKCδ eliminated ET-1 induced
FAK-S910 phosphorylation. In contrast, previous studies from our lab have
shown that PKCε was involved in ET-1 induced ERK1/2 activation but in my
study, overexpression of dnPKCε did not block ET-1 induced ERK1/2 activation.
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The only difference between these two studies was the MOI used to overexpress
dnPKCε. The earlier study by Strait et al.used 500 MOI, but in my study I only
used 100 MOI.(Strait et al., 2001) In this experiment, NRVM were infected with
the same MOI for PKCε and PKCδ, but only PKCδ was effective in significantly
reducing FAK-S910 phosphorylation and ERK1/2 activation. It is possible that the
high MOI used in Strait’s study was not specific for PKCε, but also inhibited
PKCδ. I also confirmed the FAK-S910 phosphorylation results by overexpression
of caPKCδ or caPKCε, and surprisingly both caPKCδ (Figure 27) and caPKCε
(data not shown) were sufficient to induce FAK-S910 phosphorylation and
ERK1/2 phosphorylation. Previous studies have also demonstrated that even
relatively low levels of PKCε overexpression leads to a coordinate increase in
PKCδ phosphorylation at Thr505, Tyr311, and Tyr332.(Rybin et al., 2007) This
crosstalk might be the explanation for some of the ambiguities identified in
previous studies that have used this experimental strategy. Additional
experiments with siRNAs specific to “knock down” the individual isoenzymes
should help to clarify the role of PKCε vs. PKCδ in these pathways.
Another inconsistency in my studies was the demonstration that the
classical PKC inhibitor Gö6983 did not block ET-1 induced FAK-S910
phosphorylation, but overexpression dnPKCα was at least partially effective. It is
important to note, however that previous studies were unable to demonstrate that
ET-1 caused a consistent translocation of PKCα in NRVM.(Clerk et al., 1994)
Furthermore dnPKCα may not be entirely specific for PKCα inhibition (GarciaParamio et al., 1998; Whelan and Parker, 1998), perhaps by interfering with the
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activation of other PKC isoenzymes. Base on these studies, I believe that PKCδ
was the major PKC isoenzyme responsible for ET-1 induced FAK-S910
phosphorylation.

3. SFKs in ET-1 induced FAK-S910 phosphorylation
When NRVM were treated with PKCδ inhibitor or dnPKCδ, ET-1 induced
FAK-S910 phosphorylation was only reduced by approximately 50%, suggesting
that other signaling pathways might also be involved. Several studies have
provided evidence for GPCR-dependent activation of SFKs in NRVM, and
activation is important in ET-1 induced cardiac hypertrophy. The major SFK
isoforms in NRVM are c-Src, Fyn and Yes and all three kinases can be activated
by ET-1.(Kovacic et al., 1998) In my studies, I have demonstrated that both Src
and Fyn are involved in FAK-S910 phosphorylation.
The mechanisms responsible for ET-1 induced Src and Fyn activation in
cardiomyocytes are still not clear. Previous studies have shown that Src can be
activated by FAK, Pyk2, trans-membrane activation, reactive oxygen species
(ROS) or β-arrestin.(Abe and Berk, 1999; Della Rocca et al., 1997; Dikic et al.,
1996; Schaller et al., 1994; Wan et al., 1996; Xing et al., 1994) showed that
treatment of NRVM with the antioxidants trolox or NAC, the EGF receptor kinase
inhibitor AG1478, the PDGF receptor kinase inhibitor AG1296, the FAK inhibitor
PF572338, or knocking down Pyk2 by shRNA did not prevent ET-1 induced FAKS910 phosphorylation. These results suggest that FAK, Pyk2, ROS and
transmembrane activation are not involved in this signaling cascade. I have not
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examined whether ET-1 induced FAK-S910 phosphorylation is mediated by aβarrestin-Src signaling pathway, so it is conceivable that this pathway is
responsible.
Villa-Moruzzi (2007) demonstrated that ERK5 is involved in regulating
FAK-S910 phosphorylation in Swiss 3T3 cells.(Villa-Moruzzi, 2007) Furthermore,
Src has been shown to be involved in ERK5 activation in other cell types.(Sun et
al., 2003) In this study I have shown that Src activate the MEK5-ERK5 pathway
to regulated FAK-S910 phosphorylation. Surprisingly, overexpression dnFyn did
not block ET-1 induced ERK1/2/5 phosphorylation. Thus Fyn may activate a yet
undescribed signaling pathway to also induce FAK-S910 phosphorylation.

4.

SFK

and

PKC

cross-talk

in

ET-1

induced

FAK-S910

phosphorylation
PKCδ contains multiple tyrosine phosphorylation sites, including Y52,
Y155 and Y197 in the regulatory domain, Y311 and Y332 in the hinge region,
and Y512 and Y523 in the kinase domain. Typical models of PKCδ activation
require lipid cofactor binding to determinants in the N-terminal regulatory domain
that anchor PKCδ to the membrane. This interaction promotes a conformational
change that removes the autoinhibitory pseudosubstrate domain from the
substrate-binding pocket.(Steinberg, 2004) However, PKCδ also is dynamically
regulated through phosphorylation at a conserved threonine residue in the
activation loop (T505)(Rybin et al., 2004) Rybin et al have identified a novel T505
PKCδ

autophosphorylation

mechanism

that

is

regulated

by

PKCε
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overexpression,and involves the Src-dependent phosphorylation of PKCδ at
Y311 and Y332.(Rybin et al., 2007) Several studies have also demonstrated that
Src is an upstream regulator of PKCδ in different cell types such as hepatoma
cells(Chen et al., 2011), cardiomyocytes(Rybin et al., 2007) and smooth muscle
cells.(Hsieh et al., 2009) Conversely, several studies also demonstrated that Src
activity is regulated by PKCδ in glioblastoma and smooth muscle cells.(Cho et al.,
2005; Nomura et al., 2007) The interaction between Src and PKCδ in regulating
ET-1 induced FAK-S910 phosphorylation still needs to elucidate by further
experiments.

5. ERK1/2/5 in cardiac remodeling
The interaction between Src and PKCδ in regulating ET-1 induced FAKS910 phosphorylation may be mediated by the substantial, bi-directional
crosstalk between Src and PKCδ, and may also be responsible for the
simultaneous activation of ERK1/2/5. ERKs have been implicated as important
mediators of cardiac hypertrophy in both cell culture systems and in transgenic
mouse models. The first evidence implicating the ERK cascade in cardiac
hypertrophy came from mice with cardiac-restricted Ras overexpression. These
animals developed concentric LVH with diastolic dysfunction.(Hunter et al., 1995)
Conversely, mice with cardiomyocyte-restricted dnRaf-1 overexpression (a major
Ras effector) demonstrated reduced load-induced ERK1/2 activation, and
reduced cardiac hypertrophy in response to TAC.(Harris et al., 2004) Cardiacrestricted expression of an activated form of MEK1 in transgenic mice also
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developed concentric LVH without signs of cardiomyopathy or lethality for up to
12 months of age, and showed a dramatic increase in cardiac function without
signs of decompensation over time.(Bueno et al., 2000) These studies suggest
that the Ras-Raf-1-MEK1-ERK1/2 signaling cascade plays a critical role in
cardiac hypertrophy.
Surprisingly,

ERK2-overexpressing

hypertrophy,(Molkentin

and

Robbins,

mice

2009)

did
and

not

develop

cardiac

TAC-induced

cardiac

hypertrophy was not prevented in ERK1-knockout mice.(Purcell et al., 2007)
Additionally, mice with cardiomyocyte restricted expression of dual-specificity
phosphatase 6 (DUSP6), a highly specific regulator of ERK1/2 dephosphorylation,
eliminated ERK1/2 phosphorylation at baseline and after stimulation, but did not
prevent TAC-induced cardiac hypertrophy.(Purcell et al., 2007) Nevertheless, in
DUSP6 knockout mice, basal ERK1/2 phosphorylation was increased, but the
phosphorylation of ERK5, p38 or JNK was unaffected. Dusp6 knockout mice
developed larger hearts at every age examined, which was associated with
greater rates of myocyte proliferation resulting in cardiac hypercellularity, rather
than hypertrophy. This increase in myocyte content in the heart was protective
against decompensation and hypertrophic cardiomyopathy following long-term
TAC and myocardial infarction in adult mice.(Maillet et al., 2008) These latter
studies suggest that ERK1/2 maybe not necessary in pathological hypertrophy,
but might be involved in regulating myocyte cell division.
Thus, different transgenic mouse studies have shown contradictory results.
To determine whether ERK1/2 really plays an important role in cardiac
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hypertrophy, Kehat et al. recently generated cardiac-specific ERK1/2 knockout
mice. ERK1/2 deletion did not prevent physiological or pathological hypertrophy,
but altered the hypertrophic phenotype. ERK1/2 knockout mice developed
eccentric hypertrophy rather concentric hypertrophy in response to pressure
overload, suggesting that ERK1/2 is necessary for the parallel addition of
sarcomeres, and to prevent eccentric hypertrophy.(Kehat et al., 2011)
Several studies also have shown that ERK5 plays an important role in
cardiac hypertrophy. ERK5, also known as big MAPK-1 (BMK1), has an Nterminal domain that is homologous to ERKs 1 and 2, but has unique C-terminal
and loop-12 domains.(Lee et al., 1995; Zhou et al., 1995) To determine whether
ERK5 is involving in cardiac hypertrophy in vivo, Nicol et al created cardiacspecific, constitutively active MEK5 overexpressing transgenic mice. The
constitutively active MEK5 transgenic mice develop eccentric hypertrophy that
progressed to dilated cardiomyopathy and sudden death.(Nicol et al., 2001)
Furthermore,

cardiomyocyte-specific

ERK5

knockout

mice

demonstrated

attenuated TAC-induced cardiac hypertrophy, interstitial fibrosis, and fetal gene
reactivation.(Kimura et al., 2010; Regan et al., 2002; Wang et al., 2005b) These
studies suggest that ERK5 may also play an important role in cardiac
hypertrophy.
These two distinct signaling pathways play a critical role in regulating
length vs. width remodeling of cardiomyocytes during aging or stress
stimulation.(Kehat and Molkentin, 2010a; Kehat and Molkentin, 2010b) Thus, I
speculate that in addition to their roles in regulating gene transcription, ERK1/2

and

ERK5

regulate

sarcomere

structure

by

controlling

FAK
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serine

phosphorylation. In my studies the ERK1/2/5 pathways can be activated by ET-1,
and are important in regulating FAK-S910 phosphorylation in cardiomyocytes.
Based on these findings, it is possible that ERK1/2/5 regulates sarcomere
structure through regulating FAK-S910 phosphorylation.

6.

FAK

self-regulation

in

stretch-induced

FAK-S910

phosphorylation
In early studies of stretch-induced cardiomyocyte hypertrophy, several
investigators showed that mechanical stretch activates all three MAPK family
members as well as FAK in cardiomyocytes.(Seko et al., 1999; Wang et al., 2001)
Balloon inflation to raise ventricular pressure in intact hearts also activated FAK
and ERK1/2.(Domingos et al., 2002) Other studies also have shown that FAK is
involved in mechanical stretch induced ERK1/2 activation.(Li et al., 2001; Wang
et al., 2005a) In this study I also showed that static stretch induced ERK1/2
phosphorylation is through a FAK-dependent pathway. Several studies have
shown that Src-mediated FAK-Y925 phosphorylation can provide a docking site
for GRB2 and lead to ERK1/2 activation.(Schlaepfer et al., 1994; Schlaepfer and
Hunter, 1996; Schlaepfer et al., 1998) Then it is possible for ERK1/2 to
phosphorylate FAK at S910, and this feedback regulation can further enhance
FAK’s release from the focal adhesion complex. Although I was unable to
demonstrate that the FAK kinase inhibitor prevented ERK1/2 or FAK-S910
phosphorylation in response to ET-1, it is conceivable that other FAK-
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independent pathways were activated in response to ET-1, rendering the FAKdependent pathway unnecessary.
7.

FAK-S910

phosphorylation

regulates

FAK

and

paxillin

interaction
FAK not only possesses kinase activity, but also serves as a scaffold
protein. The localization of FAK is important in regulating its own kinase function.
Overexpression of FAT domain or FRNK to replace FAK from focal adhesions
can inhibit FAK tyrosine phosphorylation.(Heidkamp et al., 2002) The FAK-S910
site is 12 amino acids away from the first helix of the FAT domain, and
phosphorylation at FAK at the S910 residue might be important in regulating the
conformation of FAT domain. X-ray crystallography and solution phase NMR
studies of the FAK FAT domain have revealed that loop 1 is longer and less
structured in solution. Loop 1 is a proline-rich region that links helix 1 and helix 2.
(Arold et al., 2002; Liu et al., 2002a) The three prolines in the hinge region may
create conformational strain due to reduced intrinsic conformational flexibility,
and thus may sample multiple conformations. Nevertheless, the biological
relevance of conformational dynamics affected by the hinge region is not clear.
The protein sequence surrounding FAK-S910 (PQEISPPPT) is also a proline-rich
region and it might have the same structural property as the loop 1 region. The
S910 phosphorylation site might be regulating the conformational change of the
FAT domain structure, and therefore regulating the susceptibility of FAK
phosphorylation at Y925, as well as ligand binding to other proteins, such as
Grb2, talin or paxillin.(Prutzman et al., 2004) The crystal structural results and co-
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immunoprecipitation studies suggest that paxillin binds to the FAT domain in a
rigid four-helix bundle conformation.(Hayashi et al., 2002a) Previous studies
have shown that FAK-S910 phosphorylation regulates the FAK and paxillin
interaction in NIH-3T3 cells.(Hunger-Glaser et al., 2003) In my studies, I also
found that FAK-S910 phosphorylation controls the FAK-paxillin interaction. The
interaction between FAK and paxillin (and perhaps between FAK and talin) is
important for FAK localization at the focal adhesion complex. During
costamerogensis, several important proteins, such as vinculin and α-actinin,
need to be recruited to the membrane. Interfering with the localization of these
proteins during new costamere formation affects sarcomere assembly in the
muscle cell.(Conti et al., 2009; Zemljic-Harpf et al., 2007) In nonmuscle cells,
FAK is important in regulating the localization of vinculin and the interaction
between vinculin and talin.(Ling et al., 2002) My results, together with those of
others, suggest that FAK-S910 phosphorylation may regulate the FAT domain
conformational change, thereby interfere with protein-protein interactions within
the costamere.

8. FAK-S910 phosphorylation regulates vinculin and paxillin
interaction
X-ray crystallographic studies have also shown that the FAK FAT domain
and the vinculin tail domain share structural similarities (Bakolitsa et al., 2004;
Bakolitsa et al., 1999), and both proteins bind to overlapping paxillin LD
motifs.(Tumbarello et al., 2002; Turner, 2000; Turner et al., 1999) Subauste et al.
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have shown that overexpression of vinculin or the vinculin hinge-tail region can
impede the interaction of FAK with paxillin, and this interaction is important for
downstream ERK1/2 activation.(Subauste et al., 2004) In addition, FAK can
regulate adhesion strength through modulating vinculin recruitment to focal
adhesions.(Dumbauld et al., 2010a; Dumbauld et al., 2010b) In myosin-II
dependent focal adhesion maturation, tension can activate FAK, leading to the
formation of a FAK/Src complex, which is necessary for the phosphorylation of
paxillin at Y31/Y118. Phosphorylated paxillin creates a binding site for vinculin,
which in turn recruits several other proteins, such as α-actinin, to the focal
adhesion complex. (Pasapera et al., 2010) In my study, I have shown that
mutation of FAK at S910 enhances the paxillin-FAK interaction, but decreases
total tyrosine phosphorylation of paxillin. Overexpression of FAK-S910A also
reduces total tyrosine phosphorylation and interferes with the paxillin-vinculin
interaction. These results suggest that FAK-S910 phosphorylation causes the
preferential binding of paxillin to vinculin over FAK in the focal adhesion complex.
In further support of this notion, a previous study indicated that vinculin can still
be recruited to focal adhesions even when FAK tyrosine kinase activity was
inhibited. I have also found that inhibition of FAK kinase activity with PF-562,271
did not inhibit FAK-S910 phosphorylation, indicating that the kinase function of
FAK is not involved in regulating ET-1 induced FAK serine phosphorylation.
Thus, this alternative pathway for vinculin recruitment (involving FAK-S910
phosphorylation by PKCδ and Src) may also enhance the paxillin–vinculin
interaction independently of FAK’s catalytic activity.
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9. FAK-S910 phosphorylation in costamerogenesis
Following isolation, neonatal and adult cardiomyocytes in culture begin to
remodel their adhesive structures to adapt to the two-dimensional culture
environment. This process includes the reorganization of costameric structures to
form adhesive structures that are structurally similar to typical focal adhesions
found in nonmuscle cells. In cultured cardiomyocytes, focal adhesion proteins
also reassemble along the cell-substratum interface in register with overlying Z
discs of the remodeled sarcomeres. (Ervasti, 2003; Hilenski et al., 1992a;
Hilenski et al., 1991; Hilenski et al., 1992b; Hilenski et al., 1989; Simpson et al.,
1993) FAK plays a very important role in regulating focal adhesion turnover in
nonmuscle cell types, especially in migrating cells.(Schlaepfer et al., 2004)
Several studies have also shown that FAK is critical for costamerogenesis and
sarcomere structure in cardiomyocytes and skeletal muscle cells.(KovacicMilivojevic et al., 2002; Kovacic-Milivojevic et al., 2001; Mansour et al., 2004;
Quach and Rando, 2006) Animal studies also confirmed that FAK is involved in
embryonic development of the heart, and the length or width remodeling of adult
cardiomyocytes under stress conditions.(Clemente et al., 2007; DiMichele et al.,
2006;

Peng

et

al.,

2006;

Peng

et

al.,

2008)

How

FAK

regulates

costamerogenesis and sarcomere reorganization remains a mystery in the
muscle cell.
In this study, I have revealed a possible mechanism of costamerogenesis
and sarcomere reorganization by FAK, which is important in growth-factor
induced

cardiomyocyte

hypertrophy.

ET-1

can

induce

FAK-S910
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phosphorylation, which is mediated by ETAR-PKCδ-Raf-1-MEK1/2/5-ERK1/2/5 or
ETAR-Src-MEK5-ERK5 signal transmission. Activated ERK1/2/5 phosphorylates
FAK at the S910 residue, leading to FAK dissociation from paxillin. This
dissociation promotes the interaction between vinculin and paxillin. This proteininteraction “switch” can stabilize the costamere complex and initiate myofibrillar
reorganization (Figure 72).
These findings may provide a new mechanism to understand how FAK is
involved in costamere assembly and sarcomere reorganization during growthfactor-induced cardiac hypertrophy.
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Figure 72. Costamerogenesis model. Hypertrophic stimuli can induce FAKS910 phosphorylation, leading to FAK dissociation from paxillin. This dissociation
promotes the interaction between vinculin and paxillin. This protein-interaction
“switch”

can

reorganization

stabilize

the

costamere

complex

and

initiate

myofibrillar
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